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ABSTRACT 
Exosomes are key mediators of intercellular communication with the capacity to 
regulate immune responses, locally and distally. Most knowledge on exosomal 
function has been gained from exosomes generated from in vitro cell cultures, which 
has helped define the role of exosomes from specific cell types. However, studying 
ex-vivo isolated exosomes from body fluids are more likely to yield clues about their 
in vivo role. This thesis aimed to gain knowledge regarding the role of human-
derived exosomes from two important organs with a well-equipped immune system, 
namely the lung and the mammary gland.  
 
In study I we studied exosomes from bronchoalveolar lavage fluid (BALF) of patients 
with pulmonary sarcoidosis and healthy individuals. We detected elevated levels of 
exosomes with an altered exosome protein profile in BALF from patients compared 
to exosomes from healthy controls. Exosomes isolated from patients exhibited pro-
inflammatory functions seen by their ability to induce inflammatory cytokine release 
(IFNγ and IL-13) in autologous peripheral blood mononuclear cells (PBMCs) and (IL-
8) in the bronchial epithelial cell line (BECs) 16HB14. These data suggest that 
exosomes may contribute to the inflammatory state of sarcoidosis.  
In order to investigate the specificity of the findings in study I relative to other 
inflammatory settings, we performed analysis of BALF exosomes from asthmatics. In 
study II we found that several surface proteins (CD36, CD63 and CD81) were 
upregulated on BALF exosomes from asthmatics during steady state and after 
allergen challenge compared to healthy controls. In addition, BALF-derived 
exosomes from asthmatics at steady state and after allergen challenge could 
stimulate secretion of leukotrienes (LTs) and IL-8 in BECs, suggesting a pro-
inflammatory function of BALF exosomes in asthmatic inflammation. 
Breastfeeding is associated with health benefits for the child with possible effects on 
allergy development. Variations in immune-composition in breast milk between 
mothers could potentially result in differences in allergic outcome. Therefore, in 
study III we sought to determine whether maternal sensitization and lifestyle could 
affect exosome composition in breast milk. Accordingly, we found that both 
maternal immune status and environmental factors have a differential impact on 
subpopulations of exosomes in breast milk with potential effects on allergic 
outcome of the child as a consequence. 
In study IV we aimed to study the effect of breast milk-exosomes on HIV infection 
based on findings suggesting a protective role of breastfeeding on HIV infection 
from mother-to-child. We report a protective role of human breast milk exosomes 
on HIV infection of dendritic cells and subsequent transfer and infectivity of T cells. 
Thus, we suggest that breast milk-exosomes might constitute one protective factor 
in milk against HIV infection in the child. 
In conclusion, this thesis provides important insights into the composition and 
function of exosomes from human BALF and breast milk. Furthermore, it sheds light 
on how different immunological conditions can perturb the function and phenotype 
of exosomes in vivo. In the future, this could have important implications for the 
development of novel treatments against inflammatory diseases using exosomes as 
targets or therapeutic vehicles. 
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1 INTRODUCTION 
1.1 OVERVIEW OF THE IMMUNE SYSTEM  
Life on earth began more than 3.5 billion years ago 1. Very early on, unicellular 
organisms already possessed an innate defense system capable of recognizing and 
destructing pathogens (virus, bacterium, prion, fungus or protozoan that cause 
disease), as well as the ability to discriminate between self and non-self. This effective, 
although limited immune defense still dominates in most organisms, and it was not 
until 500 million years ago that a sophisticated and highly diverse adaptive immune 
system emerged in jawed vertebrates 1. The acquisition of such evolutionary advanced 
system has arguably favored a significant survival advantage against lethal pathogens. 
Nevertheless, the trade-offs of having a specific immune system can be of significant 
cost: propensity for immune attack against itself (autoimmune disease). Thus, high 
levels of immune responses against pathogens need to be tightly regulated in order to 
avoid self-destruction. To achieve this, a delicate inter-cellular communication is of 
crucial importance to successfully co-ordinate the innate and adaptive arm in order to 
maintain a functional immune system. In this section I will focus on new developments 
in the field of mucosal immunology. 
 
1.1.1 INNATE DEFENSES  
The innate immune system is the first line of host defense against life threatening 
insults. It is often defined as being non-specific in their ability to recognize antigens – 
an erroneous concept since it possesses a certain degree of specificity based on its 
potential to discriminate between pathogens, commensal microbes and self-antigens. 
Body surfaces, in particular mucosal surfaces, are constantly exposed to microbes and 
are often the port of entry for intruders 2. However, upon barrier penetration, 
pathogens are instantly encountered by an array of specialized innate immune cells 
carrying pathogen-recognition receptors (PRRs), which can sense and bind conserved 
molecular patterns found on microbes, but not on mammalian cells. Sensing of such 
motifs by PRRs initiate pro-inflammatory signaling pathways in order to help combat 
infection 3.  
 
Mucous membranes - including the gastrointestinal, respiratory, reproductive and 
urinary tract - are in close interaction with the external environment 2 and are mostly 
composed of a single monolayer of epithelium. Therefore, mucosal tissues rely on 
additional defense mechanisms to ensure barrier protection, including mucus 
secretion and a particularly strong innate immune system.  
 
1.1.1.1 Mucus barrier  
 
Protection against infections at mucosal sites relies to a great extent on the barrier 
properties of the epithelial cells with its overlaying mucus layer 4. Specialized mucus-
producing epithelial cells, known as goblet cells, generate two layers of mucus; a loose 
and viscous layer of secreted (gel-forming) mucins (e.g. MUC2, MUC5AC and MUC5B) 
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and an inner layer composed by densely packed membrane-bound mucins with a 
“bottle-brush appearance” (e.g. MUC1, MUC4 and MUC13). The textbook view that 
mucus acts as an adhesive surface that arrests microbial motility, has recently been 
challenged by studies showing that mucus actually promotes bacterial movement 5. 
By maintaining microbes in a “free swimming state” it prevents bacteria from 
aggregating and generating biofilm formation that would otherwise help mediate 
bacterial infiltration and infection.  
 
Both gut- and respiratory mucosa prevents inflammation by establishing a barrier 
against bacteria and food antigens. Tissue distribution of mucins, however, differs 
between the gut and the lung with MUC2 being the most abundant gel-forming mucin 
in the gut, while MUC5AC and MUC5B predominate in the airways. Recent findings by 
Shan et al found that MUC2 in the gut can deliver tolerogenic signals to DCs in the 
lamina propia 6, thus preventing DCs from mounting inflammatory-responses against 
innocuous antigens. Furthermore, gastrointestinal mucus can inhibit colitis and growth 
of Helicobacter pylori 7, 8, reflecting the importance of mucus against gastrointestinal 
infections. In the airways, MUC5B has been shown to play indispensable roles by 
mediating removal of harmful material trapped in the mucus barrier through the 
rhythmic beat of cilia (mucociliary clearance). In fact, mice deficient in MUC5B have an 
accumulation of material in upper and lower airways leading to chronic infection 9, 
supporting the requirement of MUC5B to maintain airway homeostasis.  
 
Paradoxically, although mucins function as steric hindrance against microbes, it also 
constitutes an attachment point for pathogens to initiate cell invasion. Therefore, 
shedding of membrane-bound mucins into the extracellular milieu could mediate a 
protective mechanism against bacterial attachment and subsequent infection. In fact, 
binding of H. pylori to the cell-anchored MUC1 on intestinal epithelial cells (IECs) have 
been shown to increase shedding of the mucin from the surface 10. Additional studies 
have shown that gastric epithelial cells expressing MUC1 bind H. pylori to a less extent 
compared to MUC1-/- cells 11, which in part can be explained by the function of MUC1 
as a “shedding receptor”. The protective effect of MUC1 against infections is best 
illustrated in MUC1 deficient mice, which exhibit increased susceptibility to H. pylori 
infection compared to wild type (WT) counterparts 11. However, respiratory 
Pseudomonas aeruginosa infection in MUC1 deficient mice have instead increased 
clearance of bacteria in the airways compared to WT mice 12. In this context, MUC1 was 
able to function as an anti-inflammatory signaling molecule and inhibit TLR5-mediated 
activation of nuclear factor (Nf)-κB. Thus, it appears that MUC1 works in several ways, 
including steric- and decoy receptor functions, in addition to its anti-inflammatory 
signaling properties.  
 
1.1.1.2 Epithelial barrier and microbial sensing 
 
Although most microbes do not generally pass the mucus layer, it happens that 
pathogens succeed to penetrate and reach the epithelium. Pathogen invasion into the 
tissue often involves attachment to the epithelial surface and subsequent 
internalization. Based on the exposed location of mucosal epithelial cells (ECs), in 
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particular the airways and more so in the gut, ECs are equipped with PRRs able to 
sense and respond to commensals and pathogens expressing conserved motifs 
(pathogen-associated molecular patterns (PAMPs)) and molecules from damaged 
tissue (damaged-associated molecular patterns (DAMPs)) 13. ECs express various 
PRRs, including Toll-like receptors (TLRs), which upon stimulation associate with a 
multitude of adaptor proteins (e.g. myeloid differentiation primary response protein 
(MyD)88, Myd88 adaptor-like (Mal), Toll/IL-1 receptor domain-containing adaptor 
inducing IFNβ (TRIF) and TRIF-related adaptor molecule (TRAM)) 13. Signaling events 
propagated by these adaptor proteins generally result in the activation of Nf-κB or the 
interferon regulatory factors 3 and 7 (IRF-3 and IRF-7) that leads to the expression of 
pro-inflammatory cytokines and type I interferons 14. To date, TLR2 and TLR4 are the 
TLRs that have been most extensively studied. Activation of TLR4 signaling occurs 
when binding to the bacterial component lipopolysaccharide (LPS) expressed by 
gram-negative bacteria 15, whereas TLR2 responds to bacterial lipoproteins from 
gram-positive bacteria 16, yeast  and mycobacteria 17. 
 
Human ECs in the lung and the intestine express large numbers of TLRs 18, 19. However, 
expression levels and location of specific TLRs on ECs vary depending on the 
anatomical location and the degree of microbial exposure at the given site. Based on 
the constant exposure of ECs to PAMPs in the gut lumen, intestinal epithelial cells 
(IECs) have developed different strategies to avoid chronic TLR–stimulation. For 
instance, expression of TLR2 and TLR4 are confined to the basolateral side of human 
fetal enterocytes, and are aberrantly located at the apical side in patients with Crohn’s 
disease 18. This suggests that a polarized distribution of TLRs on IECs might be an 
important mechanism to avoid inflammation.  
 
Notably, TLR-signaling on ECs constitutes an important communication bridge 
between the external world and the immune cells located at the basolateral side of the 
ECs. For instance, Hammad et al showed that TLR4 expression on airway epithelial 
cells, but not on hematopoietic cells, are necessary and sufficient to achieve 
recruitment, activation and migration of mucosal DCs in response to inhaled endotoxin 
and to achieve allergen induced asthma in response to house dust mite 20.  
 
1.1.1.3 Communication of mucosal ECs with innate immune cells 
 
Over the past decade, major advances have occurred in our understanding of the 
crucial role of mucosal epithelium to maintain immune homeostasis and regulate 
immune reactions 21. ECs are the first cells encountering environmental stimuli and 
play an important role in the cross-communication between the external world and 
immune cells located underneath the epithelium. The immune cells that have received 
most attention in this regard are dendritic cells (DCs), monocytes, macrophages and 
the recently identified group of cells named innate lymphoid cells (ILCs) 22. However, 
ECs can also influence other innate cells, including mast cells, eosinophils and 
basophils 19. 
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1.1.1.4 Dendritic cells 
 
DCs, a type of professional antigen-presenting cells (APCs), are the “commanders-in 
chief” of the immune system. They are responsible for connecting the innate and 
adaptive immune system, and determine inflammatory or tolerogenic outcome and 
magnitude of the final immune response. During steady state, most DCs are located in 
the tissue in an immature state where they sample the environment for antigens via 
phagocytosis 23. Upon recognition of pathogens or by sensing pro-inflammatory 
cytokines, DCs will mature and migrate from the periphery to secondary lymphoid 
organs where they present antigens to, among others, T cells. In addition, DCs provide 
appropriate co-stimulation in order to differentiate and boost the expansion of 
antigen-specific T cells.  
 
DCs sense and react to microbes through multiple PRRs expressed endosomally and 
at the cell surface. One such group of receptors are the C-type lectin receptors 
(CLRs), including DC-SIGN, DEC205 and Dectin 1, which recognize carbohydrate 
domains on a variety of pathogens 24. Recently, it has become evident that several 
pathogens, including human immunodeficiency virus (HIV), target DC-SIGN to 
modulate DC-biology by interfering with TLR signaling 25 in order to avoid destruction 
and promote infection 26. In fact, binding of the HIV protein gp120 to DC-SIGN leads to 
productive infection of DCs 27 and efficient trans-infection of T cells 28. 
 
Capturing of harmless material by DCs is believed to induce antigen-specific tolerance 
whereas sensing of potentially dangerous microbes leads to inflammatory responses 
29. DCs in the skin and at mucosal sites need to cope with the challenge of balancing 
inflammatory responses against pathogens with tolerance against beneficial 
commensals. This is particularly so for DCs in the gut and lungs. It has been postulated 
that the actual tissue microenvironment conditions DC function rather than the 
existence of functionally different DC subsets 30. This is partly illustrated by the 
functional differences between DCs from anatomically different sites. For instance, the 
small intestine contains high levels of retinoic acid (RA) (vitamin A derivate), which 
confers the ability of intestinal DCs to produce its own RA and the capacity to imprint 
gut-tropic T-regulatory cells (Tregs) (cells with the ability to dampen the immune 
response) 31. However, this function can be abolished in vivo by depriving mice from 
vitamin A causing RA to be eliminated from the intestine. In contrast, splenic DCs with 
no ability to produce RA can be conditioned to do so by exposing them to a RA-rich 
environment. Furthermore, DCs can be conditioned and functionally monitored by 
microbes and/or by cytokines in the environment 32, which is unique to the given 
tissue.  
 
1.1.1.5 Dendritic cell subtypes and division of labor 
 
Although the tissue microenvironment plays a crucial role in shaping DC function, 
other factors including life history of DCs (migratory, resident, circulating), host state 
(steady state or inflammation) and activation and maturation state of the DCs, are 
likely involved in dictating DC function and final immune response 33. In addition, DC 
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function can also be attributed to the existence of functionally different DC subtypes. 
In fact, several subclasses have been identified in both mice and humans with 
functional specializations in the generation of immune responses 34.  
 
DCs can be broadly divided into two main subtypes: conventional DCs (cDCs) and 
plasmacytoid DCs (pDCs). During steady state, cDC progenitors egress from the 
bone-marrow (BM) and migrate through the blood until reaching peripheral tissues 
and lymphoid organs, followed by differentiation of distinct DC subtypes in situ 35. DCs 
at peripheral tissues are constantly patrolling to the draining LNs where they can 
initiate immune responses. However, distinct subpopulations of DCs can be found at 
different peripheral tissues. As an example, in the murine system there are at least two 
separate subpopulations of DCs in the intestine, which are defined by the expression 
of CD103 and CD11b (CD11chiCD103+CX3CR1−CD11b−, CD11chiCD103+CX3CR1−CD11b+) 36. 
Although a third population expresses high CD11c levels (CD11chiCD103-
CX3CR1+CD11b+), they are now considered macrophages due to their poor ability to 
migrate and prime T cells, among other characteristics. Similarly, two classes of cDCs 
have been found in the lung (CD103+ and CD11bhi) 37, each with distinct and 
overlapping roles in antigen presentation. In the draining LNs of lung and gut, 
migratory DCs can be distinguished from resident DCs by the expression of CD103. In 
contrast to migratory DCs, resident DCs (CD4+CD8α−CD11b+ and CD4-CD8α+CD11b+) 
stay in the draining LN throughout their life span in an immature state. The CD8+ 
population is specialized in cross-presentation of dying cells and bacteria while CD8- 
cells are more efficient in MHC class II presentation.  
 
In humans, less is known about DC subtypes and function. Nevertheless, three 
separate subtypes of DCs have been identified in blood: pDCs and two subsets of 
myeloid DCs (equivalent to mouse cDCs) (BDCA1+ and BDCA3+), the latter shown to 
correspond to LN-resident DCs 38. In addition, several migratory subtypes of DCs with 
distinct abilities to mount T cell responses have been found in human LNs 38, 
suggesting that the complexity of DC subclasses in mice seems to be present in 
humans as well. 
 
In summary, although the exact mechanisms dictating DC functions are not known, it 
is likely a dynamic process involving functionally different subtypes engaged in 
complex interactions with the tissue microenvironment – interactions that can rapidly 
change in intensity and nature during infection. 
 
1.1.2 ADAPTIVE DEFENSES  
Lymphocytes are comprised of T and B cells – the two major components of the 
adaptive immune system. When the innate immune system is not capable of defeating 
pathogens on its own, this second line of defense is taken into action.  
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1.1.2.1 T cells 
 
T cells play important roles in cell-mediated immunity. They are defined by their 
expression of the T cell receptor (TCR) complex composed by two variable αβ chains 
non-covalently linked to CD3 (composed of γ-, δ-, ε-, and ζ-subunits) 39. Differentiation 
of T cells with their designated TCR occurs in the thymus and generates a pool of T 
cells that may mount strong responses against foreign antigen but do not respond to 
self-antigens - a process called central tolerance 40.  
 
It has long been known that the αβ chains of the TCR recognize antigens presented in 
the context of the right MHC-molecule expressed by APCs (CD4 recognizes class-II 
and CD8 class-I) . The development of the human leukemia T-cell line, Jurkat, further 
helped describe the role of the TCR complex (including both the αβ chains and CD3 
molecule) in signaling transduction and monitoring T cell fate 41.  
Most of the T cell pool in mammals is located at mucosal tissues, in particular in the 
gut-associated lymphoid tissue 2. T cells play key roles in protection against mucosal 
infections 2, which is well illustrated in T-cell deficient patients which exhibit an 
increased infectious rate 42. 
 
T cells provide support to the immune system in mainly two ways: By providing 
‘helper’ function (Th cells), or through direct killing (cytotoxic T lymphocytes (CTLs)). 
CD4+ T cells are the main cells that provide helper function. They produce cytokines 
that can instruct other cells to perform specific functions or produce chemokines that 
help recruit cells to the tissue to help eliminate pathogens or aid in wound healing and 
immune-regulation. Cytotoxic T cells on the other hand mediate protection by 
secreting cytotoxic agents, cytokines and other soluble factors or through cell-surface 
interactions (Fas-Fas ligand (FasL)), which help eliminate pathogen-infected cells. 
Nevertheless, we need to keep in mind that many exceptions to the aforementioned 
functional categorization exist.  
 
During T cell development in the thymus, through successful gene rearrangement, 
each T cell acquires a TCR with a distinct binding specificity 39. At this stage, T cells 
are considered naïve (resting) and continue their migratory journey in their quiescent 
state until they reach secondary lymphoid tissues (spleen and LNs) where they have 
the potential to become activated. This requires antigen presentation (TCR/CD3 on T 
cells bound to peptide-MHC on APCs) and cognate interaction between a number of 
molecules on the cell-surface of T cells and APCs (CD28-CD80/CD86, CD27-CD70, 
OX40-OX40L, LFA-1-CD54) leading to actin-mediated membrane reorganization of 
the cells following formation of the “immunological synapse” 43. This close interaction 
between T cells and APCs ultimately induce activation of T cells, transcriptional 
programing, robust IL-2 secretion and T cell proliferation 43. However, the APC-T cell 
interaction in the context of a given cytokine milieu will support the differentiation of 
different T cell subsets. Thus, efficient T cell activation and differentiation can be 
simplistically summarized into a three-step model; 1) antigen presentation, 2) co-
stimulation, and 3) polarization generated by cytokines in the environment 44. 
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1.1.2.2 CD4+ T cell lineages 
 
T helper cells (CD4+ T cells) can be further subdivided into different subclasses, such 
as Th1, Th2, Th9, Th17 and Tregs, among others. In response to intracellular pathogens, 
APCs produce high levels of interferon (IFN)-α/β  and IL-12, which drives the 
differentiation of Th1 cells. This subset is characterized by their expression of the 
transcription factor (TF) Tbet 45 and the production of prominent levels of IFNγ and 
TNFα, cytokines that are indespensable for clearing intracellular pathogens and 
malignant cells. In contrast, IL-4 skews the differentiation of naïve T cells into the Th2 
subtype. These cells typically express the TF GATA-3, produce high levels of IL-4, IL-5 
and IL-13 and play key roles in defending the host from extracellular pathogens. In 
addition, Th2-like cytokines have the ability to promote B cells to produce IgE and IgA 
antibodies that can circulate into mucosal sites and protect against a second 
pathogen encounter.  
 
Activation of naïve T cells in a milieu rich in IL-4 and TGFβ triggers the differentiation 
of a recently described group of T cells, named Th9. As their name implies, they 
secrete the signature cytokine IL-9 (without IL-4) and express the TF GATA-3 46. 
Studies in murine disease models have suggested Th9 cells to play important roles in 
tumor protection and in the pathogenesis of diseases, such as allergy, colitis and 
experimental autoimmune encephalomyelitis 47.  
 
Infection of extracellular pathogens that are not adequately eliminated by Th1 or Th2 
cells can be eliminated by a distinct T cell subset, namely Th17 cells. Upon bacterial or 
fungal infection, large amounts of TGFβ and IL-6 can be produced by innate cells, 
which together with IL-22 and IL-23 stimulation trigger Th17 differentiation. Their 
lineage-specific TF RORγT and high production levels of IL-17 helps define their 
lineage 48. Although crucial for protection against pathogens, they are potent inducers 
of tissue inflammation and have lately been associated with the pathogenesis of many 
human inflammatory conditions 48.  
 
All of the T cell lineages mentioned play specific protective functions against 
pathogens and are vital for keeping the host healthy. However, uncontrolled activation 
of any T cell lineage may cause disease. Thus, the immune system needs to tightly 
control effector T cell responses where Tregs are considered an important checkpoint 
in this regard. 
 
1.1.2.3 T regulatory cells 
 
T regulatory cells (Tregs) are essential for preventing autoimmune responses by 
maintaining tolerance to self-antigens. This is well illustrated by their ability to prevent 
autoimmune diseases like type 1 diabetes 49. They are also crucial in preventing 
sustained inflammatory responses and have concurrently been implicated as 
regulators of chronic inflammatory conditions, like asthma 50.  
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Forkhead box protein 3 (Foxp3) is the key regulator of Treg function and 
differentiation 51. Their crucial role in preventing adverse immune reactions is best 
illustrated in patients with loss-of-function in the Foxp3 gene, which suffer from 
severe autoimmune responses, persistent eczema and colitis 52. This is replicated in the 
scurfy mouse model which lack Foxp3+ cells and concurrently show similar 
phenotypes as the human counterpart 53. Although Tregs comprise a heterogeneous 
population of cells, including those lacking Foxp3 expression (Tr1 and Th3 cells), the 
function of these cells in vivo is far more elusive. Therefore, in this section I will focus 
on, and refer to Tregs as CD4+ T cells expressing Foxp3. 
 
Tregs can be divided into two major subsets; Natural Tregs that differentiate in the 
thymus, and induced Tregs, which develop in the periphery. Development of Tregs 
can occur in response to low doses of antigen 54, commensals 55, tolerogenic DCs 56 or 
by DCs in the presence of TGFβ 57. They are commonly found at mucosal sites, where 
they are likely involved in inducing tolerance to innocuous antigens, like commensals, 
food or pollen.  
 
Several suppression mechanisms have been attributed to the function of Tregs. These 
include their ability to secrete inhibitory cytokines (such as IL-10 and TGFβ) and serine 
proteases or through the expression of membrane-bound TGFβ 58. Furthermore, 
studies suggest that Tregs can mediate suppression by modifying DC biology. In fact, 
intravital microscopy studies in the LN have shown that interaction between antigen-
specific T cells and DCs is reduced in the presence of Tregs 59, whereas the 
interactions between Tregs and DCs is increased 60.  
 
1.1.2.4 B cells 
 
B cells and their antibodies make up an essential aspect of the immune system and are 
referred to as the antibody-mediated response or humoral immunity. The 
developmental stages of the B cells occur in the BM and involves random 
rearrangements of the DNA that ultimately gives rise to a B cell pool with diverse 
antibody specificity 61. Each antibody contains a heavy chain (H-chain) and a light-
chain (L-chain) with a conserved and a variable region (the latter responsible for 
binding to antigens). B cells egress from the BM in an immature state expressing the 
antibody subtype IgM on their surface, which constitutes the B cell receptor (BCR). 
Upon reaching secondary lymphoid tissues (spleen and LNs), B cells are considered 
mature and express both IgM and IgD on their surface and can now undergo 
activation. 
 
B cell activation can occur through T cell dependent- or independent processes. T cell 
dependent activation involves binding of a soluble antigen to the specific BCR (clonal 
selection) leading to its endocytosis. Intracellular processing of the antigen generates 
fragments that can be re-expressed on the B cell surface and presented to Th2 cells in 
the context of MHC class II. Alongside, IL-4 receptors are increased on the B cell 
surface and IL-4 signaling together with additional activation signals ultimately 
triggers B cell division and antibody class switching into IgG, IgA or IgE. Additional 
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cytokines produced by Th2 cells (IL-2, IL-5 and IL-6) cause B cells to differentiate into 
plasma cells able to secrete large amounts of secreted antibodies with the ability to 
neutralize toxins and promote phagocytosis 61. Since mucosal immunity depends on 
antibodies found in external body fluids, such as tears, saliva, intestinal juice and 
breast milk, approximately 80% of the total plasma cell population is found at mucosal 
sites 2. In addition to plasma cells, long-lived memory B cells are also generated which 
undergo phenotypic changes allowing them to react more efficiently to a second 
antigen encounter. T cell independent responses on the other hand are mounted by 
polysaccharide antigens containing multiple repeating epitopes that can cross-link 
antibodies and thereby activate B cells without the need of T cell help.  
 
The textbook view of B cell generation assumes that B cells are generated in the bone 
marrow (BM). Although true, Alt et al recently broke a paradigm by showing that B 
cells can also arise in the mouse gut during a short period after birth in response to 
colonization of the microbiota 62. This observation is consistent with the evidence 
showing that also T cell differentiation is regulated by the microflora and together 
supports the ancient “jaw hypothesis” postulating that the adaptive immune system 
originated in the gut 63.  
 
1.2 EXTRACELLULAR VESICLES  
Multicellular organisms communicate through various mechanisms including cell-cell 
contact and through secreting soluble proteins and more complex entities, including 
extracellular vesicles (EVs). These vesicles can travel and reach distant locations 
where they can interact with cells and affect their biology in various ways. Although 
initially considered cell garbage, there is increasing evidence supporting their 
contribution in various biological settings, including cell-to-cell communication, 
immunity, development, neurobiology and microbiology. 
 
Mammalian cells produce many different types of vesicles, both during physiological 
settings and during disease. Due to lack of available methodology able to selectively 
discriminate between subpopulations of EVs and the lack of well-defined markers for 
specific vesicles, the research community of EVs is currently coping with an imperfect 
nomenclature. As a consequence, researchers have invented numerous names for EVs 
reflecting subcellular origin (ectosomes, exosomes, apoptotic bodies, microvesicles), 
specific function (tolerosomes) or cellular origin (prostasomes). However, a more 
generic term can be applied and in this section I will refer to exosomes as 
endosomally-derived vesicles and microvesicles as those generated at the plasma 
membrane from different cells. 
 
1.2.1 PLASMA MEMBRANE-DERIVED VESICLES 
Microvesicles (MVs), often called microparticles, ectosomes or shedding vesicles, can 
be traced back to 1946 in which researchers were studying the contribution of blood 
coagulating factors. Chargaff et al discovered that platelet-free plasma had potent 
clotting properties 64 and it was not until 20 years later that Webber and Johnson 
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found that platelets released small vesicles with pro-coagulant function 65. Over the 
past few decades, several studies have confirmed these early findings and further 
shown that additional cell types can produce MVs, including tumor cells 66. In fact, 
elevated levels of MVs with pro-coagulant activity have been found in plasma from 
patients with cancer, suggesting a contribution of these vesicles in the hyper-
coagulant state found in patients 67. Most of the current research has however focused 
on the use of MVs as disease biomarkers, whereas limited functional data is available. 
However, recent elegant work by Choudhuri et al showed that the immunological 
synapse formed between APCs and T cells is indeed a cavity filled with TCR-enriched 
MVs 68. This suggests that shedding of TCR through MVs (lacking TCR signaling 
activity), might constitute a novel mechanism to down-regulate T cell activation.   
 
MVs are phenotypically defined as 100-1,000 nm in diameter. They are generally 
believed to form at the plasma membrane through a budding mechanism involving 
loss of phospholipid asymmetry through a calcium-dependent or cytoskeleton-
dependent mechanism 69. Phosphatidylserine (PS) is often exposed on their surface 
and is thought to mediate their uptake and clearance by macrophages 70. Notably, 
there is currently no marker that distinguishes MVs from other types of vesicles, such 
as exosomes 71. However, different EVs can be categorized according to several 
features, including size, density in sucrose, morphology seen by electron microscopy, 
sedimentation, lipid composition, protein composition and subcellular origin (see 
Table 1). 
 
Table 1. Comparison of three types of EVs: exosomes, microvesicles and apoptotic vesicles. 
Feature 
EXOSOMES 
 
MICROVESICLES 
 
 
APOPTOTIC VESICLES 
 
Size 30-100 nm 100-1,000 nm 50-500 nm 
Density in 
sucrose 
1.15-1.19 g/ml ND 1.16-1.28 g/ml 
Appearance by 
electron 
microscopy 
(EM) 
Cup shape* Irregular shape and 
electron-dense 
Heterogeneous 
Sedimentation 100,000 g 10,000 g 1,200 g,  
10,000 g or 100,000 g 
Lipid 
composition 
Cholesterol, 
sphingomyelin, 
ceramide and 
phosphatidylserine 
Cholesterol and 
phosphatidylserine  
ND 
Main protein 
markers 
Tetraspanins (CD63, 
CD9), Alix and 
TSG101 
Integrins, 
metalloproteinases 
and selectins 
Histones 
Intracellular 
origin 
Endosomes Plasma membrane ND 
Main reference             72-74                   75, 76               77, 78 
*This is an artificial effect caused by dehydration during processing of vesicles for EM analysis.  
ND: not determined. Modified from 79. 
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1.2.2 ENDOSOMALLY-DERIVED VESICLES 
Exosomes, in contrast to MVs, are formed inside the cell within endosomal 
compartments. They were discovered 30 years ago during an attempt to understand 
the process involving the loss of the transferrin receptor (TfR) during red blood cell 
maturation 80. At this point in time, researchers had long been hypothesizing that the 
receptor was down-regulated by endocytosis-mediated lysosomal degradation 81. 
Surprisingly, in 1983 Harding et al found that the TfR was rarely detected in the 
lysosomal compartments but instead found at the membrane of small vesicles within 
the lumen of late endosomes 80. Seen by electron microscopy, it appeared that these 
vesicles were expelled to the extracellular environment seen by the fusion of the 
endosomal- and the plasma membrane. A few weeks later, R. Johnstone’s group 
published similar observations 82 and subsequent work by both groups helped 
establish the novel concept of vesicle-mediated receptor shedding 83, 84. Since then, 
major advances have been made in our understanding of the biogenesis and function 
of exosomes beyond their initially postulated function as mere cellular garbage 73.  
 
1.3 EXOSOMES 
1.3.1 ISOLATION AND CHARACTERIZATION OF EXOSOMES 
Exosomes can be distinguished from other types of vesicles based on their size 
(around 30-100 nm in diameter), morphology (cup shape seen by electron-
microscopy (EM)), buoyant density (1.15-1.19 g/mL), sedimentation by 
ultracentrifugation (100,000 x g), and protein composition (enriched in tetraspanins) 
(see Table 1). The most established and commonly used protocol for isolating 
exosomes involves sequential ultracentrifugation of cell supernatants or body fluids. 
However, since it is a tedious and time-consuming method, alternative isolation 
protocols have been developed, including ultrafiltration, which is less labor intensive 
and requires no special equipment 85. In addition, several commercial isolation kits are 
now available, such as “ExoQuick” from System Bioscience, which offer an “easy” and 
“quick” method for exosome purification. However, these kits are limited by the lack of 
specificity for precipitating exosomes in relation to other types of vesicles and cellular 
debris. As a result, these kits are not suitable when using exosomes for functional 
studies, but can be accurately applied for the discovery of disease biomarkers. The 
use of volume-excluding polymers like polyethylene glycol is also used for exosome 
isolation, although yielding a rather impure isolate, just like the commercial kits. Taken 
together, ultracentrifugation is therefore the only widely accepted method for 
exosome purification so far, and when combined with further methods like sucrose 
density purification or immunoprecipitation, yields an enriched population of 
exosomes.  
 
Detection of single exosomes is difficult because of their small size. They are 
impossible to detect with conventional flow cytometry. Therefore, analysis of 
exosomes by flow cytometry typically requires capture of exosomes on antibody-
coated beads that are within a detectable size (typically around 4-4.5 μm ∅). Since 
each bead has the ability to bind many exosomes, this method has the limitation of 
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not being able to quantify vesicles or to make distinctions between phenotypically 
different subpopulations. However, recent methodological advances have been made 
that enables detection of exosomes at a much higher resolution. For example, by 
using a special flow cytometer (Becton Dickinson Influx flow) equipped with a high-
power laser, it has been feasible to detect fluorescently-labeled vesicles that are 
around 100 nm 86. In addition, nanoparticle-tracking analysis (NTA) is capable of 
measuring the total size distribution of vesicles within a heterogeneous sample (~50 
nm to 1 mm) by measuring the Brownian motion of vesicles in liquid 87. However, 
several other conventional methods are regularly used to characterize exosome 
composition of whole exosome purifications, including western blot, enzyme-linked 
immunosorbent assay (ELISA) and mass spectrometry, just to name a few. 
 
1.3.2 EXOSOME BIOGENESIS 
Mature endosomes containing intraluminal vesicles (ILVs) are called multivesicular 
bodies (MVBs). These organelles have two fates; they can fuse with the lysosome for 
protein degradation, or back-fuse with the plasma membrane and release the ILVs 
into the outer milieu as exosomes.  
 
Formation of MVBs partly depends on the ESCRT- (endosomal complex required for 
transport) machinery which is composed of at least 20 proteins that form four ESCRT 
complexes ((the ESCRTs -0 (e.g. HRS, STAM1) –I (e.g.TSG101), -II, and –III) and 
associated proteins (VPS4, VTA1 and ALIX)) 88. This group of proteins recognizes and 
targets monoubiquitinylated proteins into the endosomal compartment, promotes 
membrane deformation, inward budding of the MVB membrane and final scission of 
the vesicles into the luminal space. Since exosomes derive from ILVs, it has long been 
assumed that the ESCRT proteins are involved in exosome biogenesis. In addition, the 
notion that exosomes from various cell types carry ESCRT proteins (ALIX, TSG101) 77, 
89, strongly supports an ESCRT-dependent mechanism. Accordingly, several studies 
have found a role of selected ESCRT components in the formation of exosomes. For 
instance, a recent study identified ALIX as an important component for exosome 
formation and sorting of syndecans 90. In addition, a study targeting 23 proteins of the 
ESCRT machinery in MHC class II expressing HeLa-CIITA cells showed that several 
ESCRT-components alter exosome secretion by decreasing (HRS, STAM1, TSG101) or 
increasing (VPS4) exosome release 88. Interestingly, in the same study it was found 
that cells produce a heterogeneous population of exosomes based on size and protein 
composition that are altered differently by the distinct ESCRT genes. These findings 
suggest that individual components of the ESCRT machinery have distinct roles in the 
formation/secretion of specific exosome subpopulations.  
 
Despite the accumulated evidence supporting an ESCRT-dependent mechanism in 
exosome-formation, ESCRT-independent pathways are also likely involved since 
alteration of the ESCRT machinery does not completely abrogate the formation of 
MVBs and ILVs 91. In fact, it has been established that secretion of exosomes in 
oligodendrocytes depend on a mechanism involving ceramide-formation 92. On the 
other hand, studies in melanoma cells showed that ceramide formation is unnecessary 
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for MVB- and exosome biogenesis but instead relied on the expression of the 
tetraspanin CD63 93. Furthermore, recent studies support a function of tetraspanins in 
defining exosomal protein composition by monitoring exosome cargo selection 94. 
Other components, such as the tumor suppressor protein p53 and associated 
transcript TSAP6 have also been assigned a role in exosome formation 95.  
 
The mechanism involved in the release of exosomes from the cell is far from resolved. 
However, several lines of evidence support a role of different Rab GTPases in this 
process, partly depending on the cell type. For example, Rab11 is involved in Ca+-
induced secretion of exosomes in an erythroleukemia cell line 96, whereas Rab35 
operate in oligodendrocytes 97. More recently, a study targeting 59 different Rab 
GPTases in HeLa cells found that knock-down of Rab27a or Rab27b lead to a 
significant reduction in exosome release 98. 
 
In summary, compiled results support the hypothesis that different machineries for 
exosome formation/secretion operate in different cell types. However, the notion that 
different MVBs and ILVs 99, as well as different subpopulations of exosomes exist 
within a cell, suggests that independent- or partially overlapping sorting machineries 
co-exist within a given cell type. 
 
1.3.3 EXOSOME COMPOSITION 
Many methods have been applied to characterize the molecular composition of 
exosomes, such as proteomics, lipidomics and transcriptomics. These studies have 
revealed that exosomes do not acquire random components from the originating cell, 
but are actually equipped with a selection of proteins, lipids, mRNAs and miRNA, 
suggesting a regulated exosomal sorting mechanism.  
 
Due to their endosomal origin, exosomes contain components of the endosomal 
compartment (Rab GTPases, SNAREs, Annexins and Flotillin) and the ESCRT-
machinery (ALIX, TSG101). In addition, the tetraspanins (e.g. CD9, CD63, CD81 and 
CD82), which belong to a group of membrane bound proteins found at the plasma- 
and endosomal membrane, are commonly enriched on exosomes (>100 fold relative 
to the transferrin receptor) 100. These proteins gather into microdomains and are often 
attributed as lipid raft-like, but are however distinct from lipid raft domains 101. 
Nevertheless, exosomes carry proteins that are often associated to lipid rafts, 
including glycosylphosphatidylinositol-anchored proteins and flotillin 102. Relative to 
the plasma membrane, the exosomal lipid bilayer is enriched in cholesterol, 
sphingomyelin, hexocylceramides and phosphatidylserine 74, 103, which may increase 
their stability in vivo. 
 
ExoCarta (http://www.exocarta.org), which is a database of exosomal proteins (as 
well as lipids and RNAs) have revealed the presence of several exosome-enriched 
proteins regardless of cell-origin. A few examples are the heat-shock proteins, 
metabolic enzymes, ATPases and cytoskeletal proteins. However, cell-specific markers 
can also be detected on exosomes, including A33 (intestinal epithelial-derived) 104, 
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MHC II and CD86 (APC-derived) 105 and CD3 (T cell-derived) 106. For a schematic 
picture of an exosome, see figure 1. 
 
A breakthrough in exosome research occurred when exosomes were found to carry 
both mRNA (and miRNA) that could be translated into proteins in recipient cells 107. 
Later, RNA-containing exosomes were also detected from the supernatant of other 
cell types 108 and body fluids 109 and found to carry a selected enrichment of RNAs 
compared to the originating cell. These observations opened up a whole new concept 
of exosome-mediated intercellular communication involving exchange of genetic 
material between cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Schematic picture of an exosome, with examples of molecules found in exosomes. 
 
 
1.3.4 EXOSOMES OF THE INNATE IMMUNE SYSTEM 
Virtually all immune-competent cells produce exosomes, including those of the innate- 
and adaptive arm 79. Most of the research on functional aspects of exosomes has, 
however, focused on APC-derived exosomes, in particular DC-exosomes, due to their 
potent ability to induce antigen-specific immune responses. 
 
1.3.4.1 DC-exosomes 
 
Back in 1998 studies on DC-derived exosomes found that exosomes loaded with 
tumor antigens could inhibit tumor growth in a manner that was MHC- and CD8+ T cell 
dependent 110. These studies laid the foundation for the hypothesis that DC-exosomes 
could play a role in initiating adaptive immune responses by carrying molecules 
important for antigen presentation (MHC class I and II, co-stimulatory molecules CD80 
and CD86 and adhesion molecule CD54) 111. Later on, various attempts were made to 
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scrutinize the mechanism of exosome-dependent T cell activation and it was found 
that exosomes carrying MHC-peptide complexes can directly bind to the cognate TCR 
of primed CD4+ T- 105, 112 and CD8+ T cells 113. However, in order for DC-exosomes to 
activate naïve T cells, they first need to be captured by a recipient DC, likely due to 
the requirement of co-stimulatory molecules 114 and cytokine production by DCs, and 
the need of LFA-1 on (activated) T cells for efficient binding of CD54-bearing 
exosomes 112. Once bound to the recipient cell, DCs can directly make use of the MHC-
peptide and activate T cells 105 or recycle the peptide onto their own MHC molecule 111. 
Hence, exosomes from DCs have been implicated in peptide- or MHC-peptide 
spreading to increase the number of DCs able to present a given antigen 115. 
 
Most research has been performed on exosomes from in vitro propagated bone 
marrow-derived DCs (mouse) or from human monocyte-derived DCs (MDDCs). 
Studies have shown that the maturation state of the cell can influence the ability of 
DC-exosomes to elicit an immune response. For instance, those from mature DCs 
carry increased levels of MHC class II, CD54 and co-stimulatory molecules and have an 
enhanced ability to induce T cell priming 116 and antigen-specific IgG responses in vivo 
117 compared to those from iDC. In contrast, exosomes from iDC can induce tolerance 
rather than immunogenicity, as exemplified in a mouse cardiac allograft model 118. DC-
exosomes further carry CD1d molecules, which can be loaded with lipid antigens to 
activate NKT cells, thereby helping to amplify innate and adaptive immune responses 
119. Due to the ability of DC-exosomes to induce antigen-specific immune responses, 
they are being exploited in the clinic as a promising new cell-free vaccine against 
tumors 120, 121 and evaluated experimentally as vaccine candidates for other 
pathologies. 
 
1.3.5 EXOSOMES OF THE ADAPTIVE IMMUNE SYSTEM 
1.3.5.1 T cell-exosomes 
 
T cells secrete significantly more exosomes upon activation 122. Initial studies on 
activated human T cells performed by a group in Spain in 1999, showed that exosomes 
produced by these cells carried bioactive FasL with the ability to induce apoptosis in 
neighboring T cells 123. These results provided the basis for the novel concept of T cell-
exosomes as an autocrine or paracrine mode of immune regulation. Studies have 
shown that exosomes from ovalbumin (OVA)-specific CD8+ T cells can target OVA-DC 
and induce apoptosis via Fas-FasL interactions as well as down-regulate peptide/MHC 
I expression on DCs 124. Furthermore, exosomes from OVA-specific CD4+T cells have 
also been shown to bind OVA-DC and inhibit CTL mediated immunity, likely by 
masking the MHC on DCs 125.  Taken together, compiled evidence support T cell-
derived exosomes as regulators of immune responses. 
 
1.3.5.2 B cell-exosomes 
 
As with T cells, B cells also produce more exosomes upon certain activation stimuli, 
such as in response to antigen-specific CD4+ T cells and CD40/IL-4 signaling 126. 
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Similar to exosomes from DCs, exosomes from B cells carry antigen presenting 
molecules and during cognate interaction between B- and CD4+ T cells, B cells release 
MHC-II carrying exosomes that can activate primed, but not naïve T cells 127. B cell-
derived exosomes have further been implicated as promoters of allergic responses by 
their ability to present allergens and promote proliferation and cytokine release in 
allergen-specific T cells 128. Furthermore, B-cell exosomes from Epstein Barr virus 
(EBV) infected cells can transfer EBV-proteins to non-infected B cells 129 and miRNA 
to DCs 130, suggesting exosomes as a novel inter-cellular communication mechanism 
exploited by virus. 
 
1.3.6 EPITHELIAL-DERIVED EXOSOMES 
Exosome release is not confined to the immune system but has been found in a 
myriad of other cell types, including epithelial 131 and endothelial cells 132 and cells from 
the nervous system 133.   
 
As mentioned previously, due to the location of epithelial cells at mucosal sites, these 
cells need to be in constant communication with immune cells located at the 
basolateral side in order to maintain tissue homeostasis. Hence, exosomes at mucosal 
sites, including those produced by mucosal epithelial cells, are likely involved in 
coordinating and exchanging cellular information. It was initially shown that human 
intestinal epithelial cell lines secrete exosomes at the apical and basolateral side at 
steady state, and at increased levels during inflammatory conditions 134. However, 
immunohistochemistry staining of IECs in human biopsies found only expression of 
exosome-associated markers (CD63, MHC I and II) at the basolateral side, suggesting 
a polarized exosome-secretion mechanism 135. The expression of MHC II on IEC 
exosomes and the lack of co-stimulatory molecules could suggest a tolerogenic 
function based on studies showing that liposomes carrying MHC II but lack co-
stimulatory molecules cause anergy in CD4+ T cells 136. In fact, rat IEC-derived 
exosomes, named tolerosomes, have been shown to induce antigen-specific tolerance 
when administered intraperitoneally (i.p) in rats 137 and prevent allergic sensitization in 
a model of allergic asthma 138. In contrast, studies by Van Niel et al found no 
tolerogenic effect of IEC-derived exosomes carrying OVA, but were instead capable 
of inducing a strong OVA-specific immune response when administered i.p 139. 
Furthermore, studies by Mallegol et al showed that exosomes from IECs could transfer 
and target luminal antigens preferentially to DCs at the basolateral side and lowering 
the threshold level of antigen presentation required for activation 140. Therefore, 
although exosomes released by IECs from the basolateral side seem capable of 
carrying luminal antigens that may likely interfere with immune cells in the lamina 
propia, further studies are required to elucidate their immune function and cellular 
target. 
 
Kesimer et al found that also human tracheobronchial epithelial cells release 
exosomes. These vesicles carried mucins on their surface (MUC1, MUC4 and MUC16) 
and could bind and neutralize human influenza virus 141, suggesting a potential role for 
exosomes in mucosal innate defense. More recently, immunohistochemical analysis of 
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lung tissue revealed that exosome-markes (CD63, CD81 and Rab-5b) were mainly 
confined to bronchial epithelial cells (BECs) and macrophages, suggesting that BECs 
in the lungs might be a key player involved in exosome-mediated intercellular 
communication 142. Furthermore, under the influence of IL-13, BECs significantly 
increased exosome secretion and these exosomes were able to induce the 
proliferation and chemotaxis of monocytes compared to exosomes from untreated 
cells 142. Thus, epithelial cells exposed to Th2 polarizing conditions (mimicking an 
allergic response) seem to produce enhanced levels of exosomes with the ability to 
increase inflammatory cell proliferation. Therefore, in the case of asthma, IL-13-induced 
exosome release might potentiate an ongoing inflammatory response. 
 
1.3.7 EXOSOMES IN HEALTH AND DISEASE  
Up to date, exosomes have mainly been purified from in vitro cell cultures and studied 
in vitro and in vivo in their ability to influence disease mechanism. These studies have 
revealed that exosomes can trigger, promote or even alleviate disease phenotype in a 
context dependent manner. Nevertheless, exosomes likely have important roles 
beyond pathologies due to detectable levels of these vesicles in body fluids of healthy 
individuals.  
 
1.3.7.1 Body fluid exosomes in health 
 
The lack of proper methodological tools, such as exosome KO mice and exosome-
specific markers, has put limitations on our understanding on the role of exosomes in 
vivo. Nevertheless, the presence of exosomes in all human body fluids analyzed so far, 
including urine 143, saliva 144, breast milk 145, plasma 146, and malignant effusions 147, 
suggests an important function of exosomes in vivo. Furthermore, the presence of 
detectable levels of exosomes in several body fluids at steady state suggests a role of 
exosomes in maintaining the body healthy. Accordingly, studies on exosomes from 
seminal fluid have shown to down-modulate NK function, which is thought to prevent 
immune-mediated sperm destruction 148.  Furthermore, exosomes from the placenta 
have been reported to carry FasL and can be detected in serum during pregnancy at 
higher levels in women delivering at term versus women delivering pre-term 149. Since 
FasL is involved in providing clonal deletion of lymphoid cells, these results suggest 
that placenta-derived exosomes could help protect the fetus from immune-
recognition and destruction. In fact, cultures of human placental explants were shown 
to release exosomes carrying FasL and TRAIL, which were able to induce apoptosis in 
T cells and activated PBMCs of healthy individuals 150. Furthermore, Hedlund et al 
further reported the presence of NKG2D ligands on placenta-derived exosomes with 
the ability to down-modulate NKG2D-dependent killing of PBMCs in vitro 151. Taken 
together, exosomes produced by the placenta could have a role in maintaining a state 
of immune-privilege during pregnancy in order to avoid rejection of the fetus. Blood-
born exosomes have also been implicated as immune-regulators with the ability to 
suppress antigen-specific inflammation in a Fas-FasL dependent-manner 152 or induce 
antigen specific tolerance in a mouse model of allergic asthma 138. Thus, exosomes in 
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blood might be involved in dampening antigen-specific immune responses and could 
play a role in preventing autoimmunity and/or allergic responses. 
In summary, these results indicate that exosomes present in body fluids during steady 
state may act as regulators of immune responses. 
 
1.3.7.2 Exosomes in disease 
 
Exosome research has greatly focused on the role of tumor-derived exosomes in 
mediating disease and as potential diagnostic biomarkers. Accumulating functional 
data have established a role of tumor-derived exosomes as a mechanism of immune-
escape by inhibiting NK- and T cell function 153, blocking DC maturation 154, inducing 
myeloid-suppressor cells 155, or enhancing Treg activity 153. Furthermore, melanoma-
derived exosomes have been shown to regulate tumor growth and metastasis in vivo 
by transferring the oncogenic protein MET to bone-marrow progenitor cells 156. The 
increase in levels of exosomes in plasma from cancer patients 157, 158 further supports a 
role of exosomes in tumor pathogenesis.  
 
Exosomes have also been linked to the spread of proteins involved in 
neurodegenerative disorders and autoimmune diseases. For instance, the amyloid-β 
peptide involved in the pathogenesis of Alzheimer’s disease (AD) can be secreted 
within exosomes 159. Notably, accumulation of exosome-associated proteins within 
plaques of AD patients further reinforces a role of exosomes in AD pathogenesis. 
Similarly, α-synuclein, which is central in the pathogenesis of Parkinson’s disease, can 
be released by cells through exosomes 160, indicating a potential role of exosomes in 
accelerating disease. Likewise, exosomes isolated from the synovial fluid of individuals 
with rheumatoid arthritis (RA) carry autoantigens (citrullinated proteins) involved in 
disease pathogenesis 161. In addition, exosomes released by fibroblasts obtained from 
the synovial fluid of RA patients carry membrane-bound TNFα which exhibit cytotoxic 
functions and can render T cells resistant to apoptosis 162.  
 
1.3.8 EXOSOMES AND PATHOGENS 
Since most data in the area of exosomal immunology have focused on their role in 
cancer, relatively limited data is available on their role in microbial pathogenesis. It has 
been reported that single cell eukaryotic pathogens including the fungi Cryptococcus 
neoformance 163 and Malassezia sympodialis 164, and the protozoan Leishmania major 
165 secrete vesicles that carry virulence factors thought to help spread disease. 
Furthermore, cells infected by intracellular pathogens (e.g. bacteria, fungus and 
parasites) can also secrete exosomes carrying PAMPs, which can limit or spread 
infection, likely depending on the type of pathogen and the target cell 166. For instance, 
exosomes from peripheral blood of mice infected with malaria (Plasmodium yoelii) 
carry parasite proteins, which upon transfer to naïve mice can promote survival and 
clearance of the parasite upon infection 167. On the other hand, DCs infected with the 
yeast M. sympodialis can release nanovesicles that can trigger IL-4 production in 
autologous PBMCs of atopic eczema patients to a higher extent than in healthy 
individuals 164.  
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Exosomes have further been implicated in virus infection. The ‘Trojan horse’ 
hypothesis has been postulated for retroviruses, such as HIV, and suggests that virus 
make use of the exosomal-biogenesis machinery in order to avoid immune recognition 
and increase dissemination 168. For instance, Herpes simplex virus-1 envelope 
glycoprotein B has been shown to deviate HLA-DR into the exosomal pathway and 
therefore circumvent its target to the cell-surface 169. Furthermore, HIV has been 
reported to incorporate the viral protein Nef to exosomes, thus triggering apoptosis in 
bystander T cells 170. Finally, EBV has been shown to encapsulate EBV-specific miRNA 
into exosomes with potential repression effects on target genes in recipient- non-
infected cells 130.  
 
1.3.9 EXOSOMES IN THERAPY 
The ability of exosomes to shape immune responses has also lead to their use in 
immunotherapy, particularly as a vaccine treatment against cancer. So far, two phase I 
clinical trials have included exosomes from iDCs loaded with tumor antigens as 
vaccine treatment in patients with melanoma and non small cell lung cancer 120, 121. 
Although exosomes were well tolerated in patients, they were shown to have limited 
therapeutic benefits. Thus, efforts are made to improve immunogenicity of exosome 
tumor vaccines 119, 171.  
 
Since exosomes contain proteins and genetic material that can be delivered to target 
cells, they are considered well suited as vehicles for drug delivery and gene therapy. In 
addition, the advantage of using such vesicles, as opposed to other delivery vectors is 
that they are biocompatible, immunologically inert, can be patient-derived and have 
the ability to cross the blood-brain-barrier 172. In fact, exosomes loaded with siRNA 
carrying a brain-specific peptide on their surface were able to deliver strong RNAi 
responses specifically to cells in the brain of mice 173. In addition, exosomes from 
human plasma have been shown to deliver siRNA to monocytes and lymphocytes and 
mediate efficient RNAi responses 174. Current studies are also exploiting exosomes as 
potential gene therapeutic vehicles in cancer. One proposed strategy involves the 
loading of exosomes with exogenous miRNA with the aim to repress translation of 
pathology-related genes in tumor cells 175. 
 
Due to the involvement of exosomes in the pathogenesis of several diseases they 
could potentially be used in the future as therapeutic targets by: i) interfering with 
exosomal release (e.g. blocking ceramide production, certain Rab GTP-ases, or 
interfering with syntenin-syndecan interactions), ii) inhibiting exosome-uptake or iii) 
blocking pathogen-promoting components on exosomes. However, although 
exosome biology is considered a promising new therapeutic research avenue, it is still 
at an emerging state, and further knowledge on exosome biogenesis, function and 
mode of cell-interaction is required for their translation into the clinic.  
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1.4 MUCOSAL IMMUNOLOGY 
Organs, like lung, gut and mammary gland have evolved mechanisms to respond 
adequately to both dangerous and non-dangerous triggers. However, these 
mechanisms sometimes fail to respond appropriately, leading to inflammation and 
disease development, such as pulmonary sarcoidosis, food allergy, asthma or mastitis. 
 
1.4.1 AIRWAYS 
1.4.1.1 General anatomy 
 
The respiratory tract can be divided into two sections: the upper (including nose and 
nasal cavity) and the lower compartments (trachea dividing into bronchi, bronchioles 
and alveoli). The human lung can make room for 5 L of air with its surface over 120 m2 
176, which is comparable to the surface area of a medium-sized house. This is due to 
the presence of millions of alveoli (~480 million) located at the end of the conducting 
airways, each having a diameter of approximately 0.2 mm 176. The upper respiratory 
tract and the trachea are lined with mucus secreting goblet cells and ciliated 
epithelium that trap antigens and clear it away by their rhythmic beat. By contrast, a 
thin, non-ciliated Type I and II epithelium surround the alveoli to allow efficient 
diffusion of gases. However, air does not only contain gases, but carries also pollution, 
fungal spores, bacteria, virus and allergens at various amounts depending on the 
environment. Therefore, efficient antigen handling and removal is key to maintain 
safety in the lungs.  
 
1.4.1.2 Antigen uptake in the lung 
 
Despite the enormous antigen exposure in the lungs through breathing air, adverse 
pulmonary immune responses are relatively rare. This is due to the tightly balanced 
immune mechanisms that govern the lungs and that function to direct immune 
effector responses towards harmful pathogens, while inducing tolerance against 
innocuous microbes or particles. In this regard, proper antigen processing and 
handling by lung APCs likely play important roles in maintaining lung homeostasis.  
 
A large body of literature have identified lung DCs and alveolar macrophages (AM) as 
the main cells responsible for antigen uptake 177. However, in contrast to AM, DCs are 
the major cell type responsible for carrying antigens to the draining LNs and inducing 
T cell responses 178. Three subsets of DCs can be found in the naïve lung; a small 
number of pDC and two migratory subtypes, CD103+ and CD11bhi 37. Although both 
migratory subtypes have shown to be stimulatory rather than tolerogenic 179, 180, they 
have been proposed to have functionally distinct roles. For instance, studies by Rio et 
al showed that CD103+ DCs nearly exclusively promote CD8+ T cell activation whereas 
CD11bhi DCs induce proliferation of CD4+ T cells 181. In contrast, AM which comprise 
~95% of the immune cells in bronchoalveolar lavage (BAL), are considered poor 
antigen presenting cells and non-migratory. Nevertheless, they have recently been 
suggested to play key roles in tolerance induction by promoting the development of 
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Tregs 182. Furthermore, alveolar epithelial cells (AEC) have also been shown to function 
as APCs 183. During inflammation, AEC Type II up-regulate MHC class II on their surface 
and TGFβ secretion, leading to increased conversion of T cells into antigen-specific 
CD4+Foxp3+ Tregs. 
How DCs that mainly reside in the tissue during steady-state get access to luminal 
antigens is a matter of debate. Tracheal preparations have revealed DCs protruding 
their dendrites into the airway lumen 184. Further studies supports this notion by the 
observation that lung DCs are able to capture fluorescently labeled antigens that are 
too large to pass the epithelium 185. Taken together, these studies suggest that at least 
tracheal DCs possess mechanisms to reach across the airway lumen. However, the 
presence of these protrusions during steady state and their relevance to the whole 
lung is still elusive. Recent studies trying to address this question reached unexpected 
results. Using a technique allowing to image living tissue, Thornton et al found that 
during steady state, DCs mainly protrude dendrites across the epithelial barrier in the 
alveoli 178. Taken together, it is tempting to speculate that during steady state, a 
functional epithelial barrier together with AM are involved in promoting tolerance to 
harmless antigens. However, potentially harmful pathogens that manage to override 
this line of defense can be picked up by DCs in the lower airways and induce T-
effector immunity.  
 
1.4.1.3 Respiratory inflammation 
 
In spite of the many regulatory mechanisms in the lung aiming to prevent pathologies, 
it occurs that the system fails to sustain a healthy relationship between the antigenic 
burden and the tissue, thus triggering pulmonary inflammation. Different inflammatory 
lung diseases (e.g. asthma, COPD and sarcoidosis) display distinct inflammatory 
mediators and cellular infiltration profiles. However, characteristic features of 
inflammation can be found in most inflammatory lung diseases. 
 
Inflammation is initiated in response to danger signals (PAMPs or DAMPs) that trigger 
innate responses, often involving airway epithelial cells and/or airway macrophages. 
These cells express PRRs that sense and responds to pathogens by producing 
inflammatory mediators, such as oxygen species, pro-inflammatory cytokines and lipid 
mediators 186, 187. These inflammatory factors can directly affect the inflammatory 
response. Alternatively, they can indirectly support the response by facilitating 
recruitment of inflammatory cells from the blood to the tissue by up-regulating 
adhesion molecules (e.g. VCAM-1, E- and P-selectin) on endothelial cells, which bind 
and arrest cells to the capillary wall. Chemokines produced by lung epithelial cells (e.g. 
RANTES 188, CCL20 189, MCP-1 and IL-8 190), further helps direct the migration of cells 
egressing from the blood to the tissue. Upon infiltration, cells can aid in the 
inflammatory response by producing additional chemokines, driving additional 
recruitment of inflammatory cells to the site of inflammation, and by producing pro-
inflammatory mediators that can stimulate cell activation and tissue damage 191. 
A polarized Th1-skewed response is characteristic following lung infection by 
intracellular bacteria and by virus, whereas Th2-polarized immunity predominates in 
response to parasites or allergic responses, such as allergic asthma. 
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1.4.1.4 Etiology of sarcoidosis 
 
Sarcoidosis is a disease that often manifests in granuloma formation of the affected 
organ, typically the lungs (90% of patients) 192. The etiology of sarcoidosis is currently 
unknown. However, several environmental triggers have been (modestly) associated 
with sarcoidosis, including agricultural employment, mold or mildew, musty odors at 
work and pesticides 193. In contrast, environmental factors like animal dust, feather- or 
down pillows and smoking 194 have surprisingly been negatively associated with 
sarcoidosis 195. Nevertheless, no single cause of sarcoidosis has been identified as of 
yet.  
 
Extensive work supports Mycobacterium tuberculosis (MTB) infection as a strong 
candidate etiological agent for sarcoidosis 196. Indeed, mycobacterial DNA has been 
extracted from sarcoidosis tissues in a significant portion of patients 197. Furthermore, 
Th1-mediated immune responses against several mycobacterial antigens, including 
catalase-peroxidase (mKatG), have been described in patients 198. In addition, patients 
with tuberculosis (TB), a disease caused by M. tuberculosis infection, show remarkable 
clinical and radiological similarities to sarcoidosis. For instance, granuloma formation is 
a hallmark of both TB and sarcoidosis that exhibit subtle differences (necrotizing cells 
in the center of the granuloma in TB while usually absent in sarcoidosis) 199.  
 
In support of the view of sarcoidosis as an infectious disease, microbiological studies 
have shown that transplantation of sarcoidosis tissue cause granuloma formation in 
transplanted mice and following organ transplantation in humans 200. Furthermore, 
injecting sarcoidosis tissue into the skin of patients, called the Kveim test, results in 
granulomatous inflammation in sarcoidosis positive patients. This clinical examination 
used to be a standard diagnostic procedure of sarcoidosis. However, since sarcoidosis 
might be transmissible, it is rarely used in the clinic nowadays.  
 
Up to 35 % of sarcoidosis patients have Löfgren’s syndrome - an acute form of 
sarcoidosis with favorable prognosis often leading to total remission. Löfgren’s 
syndrome is more common in European populations, in particular Scandinavians, 
suggesting a strong genetic influence. In fact, genetic predisposition to the disease 
exists and is highly associated with the HLA-class II molecule, in particular the DRB1 
alleles 201. For instance, HLA-DRB1*01 and HLA-DRB1*04 are thought to protect, 
whereas DRB1*03, DRB1*011, DRB1*012, DRB1*14 and DRB1*15 represent risk factors for 
sarcoidosis. Furthermore, HLA-DRB1*03 positive patients with Löfgren’s syndrome run 
a very favorable disease course, while DRB1*03 negative patients have a more 
protracted disease that requires careful follow-up 201.   
 
In summary, sarcoidosis is currently considered a heterogeneous disease likely 
triggered by multiple environmental factors that when combined with genetic 
predisposition can culminate in disease. 
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1.4.1.5 Immunology of sarcoidosis 
 
The pathophysiology of pulmonary sarcoidosis likely involves an aberrant immune 
response against different antigenic triggers in genetically predisposed individuals 201. 
Common pathological features can be found in patients, such as non-caseating 
granuloma formation in the lungs with associated inflammation. In spite of this local 
inflammatory response, sarcoidosis patients often simultaneously exhibit a paradoxical 
state of cutaneous anergy to skin test antigens 202.  
 
In an attempt to describe the paradoxical immunity of sarcoidosis, Mathew et al found 
that the peripheral anergic state in patients was associated with a diminished DC 
function 202. They speculated that the lower ability of DCs from patients to stimulate T 
cells could be due to an abnormal antigen uptake or presentation. Another plausible 
explanation for a reduced peripheral immunity is the marked increase in CD4+ Tregs in 
the periphery of sarcoid granulomas, in BALF and in peripheral blood of patients with 
active disease. 203. These cells showed a potent ability to suppress T cell proliferation 
but could, however, not completely inhibit TNFα secretion, which may account for 
their inability to control granuloma formation. 
 
Pulmonary sarcoidosis is often characterized by increased CD3+CD4+ T cells in BALF 
with an increase in the CD4+/CD8+ T cell ratio 204 with activation markers being 
overexpressed in T cells from BALF compared to blood 205. These activated T cells 
produce high levels of Th1-cytokines like IL-2, TNFα and IFNγ, whereas IL-4+ T cells are 
hardly detectable in sarcoidosis BALF 206. NKT cells, which are known to be important 
in suppressing Th1-biased immune responses 207, have further been found at reduced 
levels in blood and BALF of patients 208.  
Granuloma formation is composed by a core of epithelioid-cells (activated 
macrophages resembling epithelial cells) and multinucleated giant cells (fused 
macrophages) surrounded by a ring of B cells, mast cells and predominantly CD4+ and 
occasional CD8+ T cells. These cells primarily secrete Th1-biased cytokines including 
IL-2, TNFα and IFNγ, which help sustain granuloma formation and attract additional 
inflammatory cells 209. 
 
Most individuals with sarcoidosis have full remission of disease without signs of tissue 
damage. However, in a portion of patients, the disease evolves into a chronic state 
that can progress into lung fibrosis leading to morbidity 210. Accordingly, it has been 
postulated that disequilibrium between effector and regulatory responses might exist 
which may drive the transmission from acute to chronic disease. This is supported by 
the observation that during acute disease (often following remission), Tregs from 
affected lesions dampen certain T cell inflammatory responses 203, whereas Tregs in 
chronic stages seem incompetent in this regard 211. However, further studies are 
required to fully understand the immunological steps leading to severe stages of 
disease. 
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1.4.1.6 Asthma definitions  
 
Similar to sarcoidosis, asthma comprises a heterogeneous group of conditions likely 
reflecting the diverse genetic and environmental factors that underline asthma 
pathogenesis. Early definitions of asthma involved two phenotypes: extrinsic asthma 
(often developed during childhood and associated with production of IgE antibodies) 
or instrinsic asthma (later onset and not dependent on allergic sensitization). These 
definitions are now considered biased and do not capture the diversity of asthma 
phenotypes. Therefore, researchers have developed unbiased approaches, including 
different statistical analysis methods, in order to better define asthma characteristics. 
A study conducted in 2009 made major advances in this regard. Based on molecular 
phenotyping of bronchial biopsies from a group of patients with mild-to-moderate 
asthma, Woodruff et al dichotomized patients into a “Th2 high” and a “Th2 low” 
subpopulation. The “Th2-high” asthma phenotype exhibited higher levels of IL-13 and 
IL-5 mRNA in the tissue compared to “Th2-low” patients, greater numbers of 
eosinophils and mast cells in BALF and allergen-specific IgE in blood serum. Therefore, 
these studies support the novel definition of asthma based on degree of Th2-driven 
inflammation and further suggests that alternative, non-Th2 driven mechanisms, might 
be more prominent in a subgroup of patients (Th2-low).  
 
1.4.1.7 Innate immune responses in asthma  
 
Similar to other lung inflammatory diseases, asthma pathogenesis often starts at the 
airway epithelium. In addition to its barrier function, the epithelium can sense various 
insults, it being allergens, pathogens or cigarette smoke and respond by producing a 
series of inflammatory mediators and antimicrobial peptides 212. It has been shown that 
injured epithelium releases IL-25, IL-33 and thymic stromal lymphopoietin, which in 
turn can activate NKT cells, mast cells, eosinophils, basophils and innate lymphoid cells 
2 (ILC2) 213, 214. The ILC2 subclass is able to produce high levels of Th2 cytokines (IL-13 
and IL-5) in response to epithelial damage. Furthermore, they also respond with a 
similar cytokine production profile upon sensing IL-33 produced by virus infected 
alveolar macrophages 215. This provides a previously unappreciated link between 
allergen-induced and virus-induced Th2-drive immune responses. Ultimately, it is 
believed that a damaged epithelial barrier could more readily provide the entry of 
otherwise innocuous antigens. Thus, entry of such antigens into a Th2-rich cytokine 
environment supported by the innate immune compartment, could drive the 
differentiation of Th2 cells and subsequent production of IgE antibodies 214.  
 
1.4.1.8 Lipid mediators in asthma  
 
Leukotrienes (LTs) are a group of potent pro-inflammatory lipid mediators involved in 
normal host-defense and in the pathogenesis of various inflammatory diseases, 
including asthma 216. They are rapidly produced by eosinophils, basophils, mast cells 
and alveolar macrophages upon activation at the site of inflammation 217. For a 
schematic image of the 5-lipoxygenase (5-LO) synthetic pathway, see figure 2. The 
synthesis of LTs involves an enzymatic cascade initiated by the cytosolic enzyme 
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phospholipase2 (cPLA2), which releases arachidonic acid (AA) from the nuclear 
membrane 218. The permanently membrane bound protein FLAP (5-LO activating 
protein) is believed to transfer AA to activated 5-lipoxygenase (5-LO), which then 
catalyses the formation of 5-hydroperoxy eicosatetraenoic acid (5HPETE) and further 
conversion to the unstable epoxide leukotriene A4 (LTA4) 
219. In neutrophils and 
macrophages, this occurs at the nuclear membrane. Two different enzymes can then 
rapidly metabolize LTA4: the cytosolic enzyme LTA4 hydrolase (LTA4H), which 
converts LTA4 into LTB4 (ligand of receptors BLT1 and BLT2), and the nuclear 
membrane enzyme LTC4 Synthase (LTC4S), which conjugates reduced glutathione to 
LTA4 forming LTC4. The lipid mediator LTC4, and its metabolic products LTD4 and 
LTE4, are called the cysteinyl leukotrienes (cysLTs) and bind to receptors CysLT 1 and 
2 216.  
 
CysLTs are potent bronchoconstrictors in humans and have therefore been of special 
interest in asthma research. Additional biological effects of cysLTs include increased 
blood vessel permeability, increased mucus secretion, airway remodeling and 
eosinophilic chemotaxis 219. LTB4 is a potent chemotactic factor, mainly attracting 
neutrophils, mast cells and monocytes and it has been related to several lung-
associated inflammatory diseases 220. Three receptor antagonists targeting CysLT1 
have been developed and are commercially available (pranlukast, montelukast and 
zafirlukast) 217, while CysLT2 and BLT1/2 receptor antagonists are still under 
investigation. 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. The 5-lipoxygenase (5-LO) pathway of arachidonic acid. Redrawn from 221. 
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1.4.1.9 Adaptive immune responses in asthma  
 
The prevailing paradigm of asthma pathology involve; a Th2-driven immune response 
with elevated production of IL-4, IL-5 and IL-13 leading to the recruitment and 
activation of inflammatory cells to the lungs. This generates mucus hypersecretion, 
pulmonary inflammation, B-cell isotype switching, and airway hyperresponsiveness. 
However, T-cell derived adaptive immune responses in asthma is not limited to the 
Th2 linage. This is particularly true in a subgroup of patients where therapeutic 
strategies to suppress Th2-responses have proven ineffective in clinical trials 222.  
 
More recently, Th17, Th9 and Tregs have been considered important players in asthma 
pathogenesis. It has been hypothesized that the increased levels of Th2 cells in the 
lungs of asthmatics could partially be due to disequilibrium between effector and 
regulatory mechanism. This is supported by studies showing that Tregs from atopic 
individuals have reduced suppression function and in some cases the absolute 
numbers of Tregs are reduced 223. 
Emerging evidence suggests that Th17 cells might also contribute to the development 
of asthma, at least in a subgroup of non-atopic patients having severe airway 
neutrophilia. This is due to the known role of IL-17 on neutrophil recruitment 224. 
However, studies using animal models of allergic inflammation has shown that IL-23, 
another Th17-derived cytokine, is a potent inducer of neutrophilic and eosinophilic 
airway inflammation 225. Nevertheless, it is unclear how far the findings made in 
allergen challenged animal models can be extrapolated to human disease since they 
don’t reproduce all features of human asthma.  
 
In conclusion, although major advances have been made to understand the 
complexity of asthma pathogenesis, more studies are required to better categorize 
different types of asthma with the hope to generate future targeted therapies. 
 
1.4.1.10 Bronchoalveolar lavage fluid-derived exosomes 
 
Bronchoalveolar lavage-fluid (BALF)-derived exosomes from healthy individuals carry 
antigen-presenting- (MHC I and II) and co-stimulatory molecules (CD80 and CD86) 226, 
suggesting a potential role of exosomes in local immune responses. Studies by Prado 
et al showed that BALF exosomes from allergen-tolerized mice could confer 
protection against allergen-induced inflammation in recipient mice 227. In contrary, 
preliminary results by the same group imply that BALF exosomes from allergen-
sensitized mice can instead aggravate an allergen specific response (N. Prado, C. 
Thery, M. Villalba, R. Rodriguez, and E. Batanero, unpublished results) 227. Furthermore, 
follow-up studies showed that pre-treatment with BALF exosomes from tolerized 
mice also provided protection against subsequent sensitization with an unrelated 
allergen, an effect described as “bystander suppression” 228. Together, these studies 
suggest that exosomal function varies with the physiological state of the lung. 
Furthermore, it also sheds light on the potential use of “tolerogenic” exosomes as 
prophylactic or curative treatment against allergies. 
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A study in mice recently shed some light on the cellular source of BALF exosomes. 
The study group reported an increase in exosome production in BALF upon allergic 
sensitization and data suggest that epithelial cells and macrophages are the main 
cellular source for exosome-production 142. In addition, exosomes released by 
bronchial epithelial cells (BEC) during an inflammatory condition (IL-13), but not from 
naïve cells, were able to promote monocyte proliferation, suggesting a pro-
inflammatory function of BEC-derived exosomes during pulmonary inflammation. 
BALF exosomes have also been implicated in immune responses to intracellular 
pathogens. Accordingly, BALF-exosomes isolated from Mycobacterium bovis infected 
mice carried bacterial antigens and could stimulate TNFα production in naïve 
macrophages 229. 
 
Despite the importance of exosomes in inter-cellular communication, limited data is 
available on BALF-exosome function and characterization in humans. During the work 
with this thesis we reported the presence of miRNA in BALF-derived exosomes from 
both healthy and asthmatic patients 230. Remarkably, there were significant difference 
in the miRNA profile between the control group and patients with unprovoked, stable 
asthma, suggesting a potential role of BALF-exosomes in the asthma-associated 
inflammatory response. 
 
In conclusion, studies suggest that BALF exosomes might be involved in mediating 
local immune reactions. However, the type of immune response elicited by BALF 
exosomes is likely context-dependent. 
 
1.4.2 MAMMARY GLAND 
1.4.2.1 Lactation 
 
The mammary gland is a unique organ in mammals with the specific function to 
produce and secrete milk to the offspring. Therefore, it is not until the female becomes 
pregnant that the mammary gland reaches full maturation, causing extreme 
modifications of the gland in order to transform into a milk-secreting organ. Similar to 
the lower airways, the lactating mammary gland is composed of a branching network 
of alveoli that form hollow cavities surrounded by a single epithelial cell layer able to 
secrete milk. Myoepithelial cells positioned underneath the milk-secreting epithelium 
can respond to oxytocin hormone and contract, thus helping to eject the milk from the 
alveolar lumen 231.  
 
Milk-secreting epithelial cells produce milk through five distinct secretory pathways 
(see figure 3) 231. The exocytic pathway (pathway I) mediates the secretion of aqueous 
solutes (e.g. milk proteins, lactose, oligosaccharides and calcium) while the milk-fat 
globule (MFG) pathway (pathway II) provides the secretion of lipids by forming lipid-
enclosed membrane vesicles (the MFG). The transcytosis pathway (pathway III) 
promotes endocytosis of exogenous material at the basolateral side of the epithelium, 
such as secreted IgA (sIgA), leading to the formation of mature endosomes, which can 
fuse with lysosomes for protein degradation or fuse with the apical side of the plasma 
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membrane for exocytosis. The membrane transcellular pathway (pathway IV) involves 
the direct fusion of small molecules (glucose and amino acids) and water across basal 
and apical plasma membranes. Finally, a paracellular route exists (pathway V) but is 
only available during pregnancy or during mastitis (breast inflammation). During these 
conditions, low molecular weight molecules from serum and interstitial fluid can enter 
through this route. 
 
 
Figure 3. Milk secretory pathways (I-V) by lactating alveolar epithelial cells. I) The exocytic pathway, II) milk fat 
globule forming pathway, III) the transcytosis pathway, IV) the membrane transport pathway and V) the 
paracellular pathway. MFG: milk fat globule, ME: myoepithelial cells, N: nucleus, RER: rough endoplasmic 
reticulum, BM: basement membrane. Redrawn from 231.  
 
1.4.2.2 Breast milk 
 
Breast milk has long been known to contain all necessary nutrients for the 
development of the newborn. The concept that milk also carries immune-modulatory 
components has also been acknowledged for quite some time. In fact, studies 
performed by Paul Ehrlich back in 1892 showed that immunity against plant toxins was 
transferred to the fetus in utero and via breast milk 232. The protective substance was 
later shown to be due to antibodies present in milk. Ehrlich referred to this effect as 
“passive immunity” and was rewarded the Nobel Prize in 1908 for his findings, which 
helped to pave the way for modern immunology. 
 
Human breast milk is enriched in sIgA, followed by IgM and IgG. These antibodies 
provides passive immunity to the child that at birth is immunologically naïve and 
deprived of its own IgA production until almost 30 days after birth 233. Antigen-
specific IgA can be transported to the milk from the blood or produced by IgA+ B cells 
homed to the mammary gland from the intestine or lungs through a CCL28-
dependent mechanism 234. Ultimately, sIgA transferred to the neonate can provide 
protection against intestinal and respiratory pathogens by preventing their adherence 
to the newborn gut 235. 
 
Human breast milk also contains growth factors (e.g. insulin-growth factor and 
epidermal growth factor) likely having beneficial effects on both the mammary gland 
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and the gastrointestinal tract/immune system of the child 236. Cytokines like IL-1, TNFα, 
IL-6, TGFβ and IL-10 are present in milk and several cytokines can be induced in vitro 
in T cells and macrophages isolated from milk. Macrophages are the most abundant 
cell type in colostrum (early milk secreted 3-6 days after delivery) (40-50%) followed 
by neutrophils (40-50%) and lymphocytes (5-10%) 237. Many studies have shown that 
milk leukocytes are taken up by the newborn 238-240, suggesting that they confer active 
immunity to the child. Other components with immune protective factors in milk are 
fatty acids, lactoferrin, lysozyme, oligosaccharides and antioxidants. Lastly, recent 
work has shown that human breast milk also provides commensal and probiotic 
bacteria to the infant gut with potential effects on the development and maturation of 
the child’s immune system 241. 
 
1.4.2.3 Breastfeeding and allergy 
 
It is well documented that breastfeeding protects the child against diarrheal diseases 
and is currently the most effective intervention against mortality of children under 5 
years of age 242. However, the relationship between breastfeeding and IgE-mediated 
allergic disease remains controversial and has been under intense debate for a long 
time. I will here outline a few of the many reports showing evidence for and against a 
protective effect of breastfeeding against development of allergy. 
 
A large longitudinal Swedish birth cohort study (BAMSE) found that exclusively 
breastfed children (≥4 months) had a reduced risk of asthma and atopic dermatitis at 
the age of 2 243. However, this study defined allergies only based on symptoms and not 
IgE-sensitization. Follow up studies by Kull et al found that breast-feeding for ≥4 
months protects against asthma 238 and eczema 239 also at 4 years of age, irrespective 
of IgE sensitization to common allergens. A large Australian longitudinal study 
(Tasmanian Asthma Study) following patients from the age of 7 to the age of 44 
years, showed that exclusive breastfeeding for the first 3 months of children with a 
maternal history of atopy led to a reduced risk to develop asthma before the age of 7 
years 244. However, they found an increased likelihood to develop asthma after the age 
of 7. This study did however not take into account IgE-sensitization. Conversely, in a 
German cohort it was reported that exclusive breastfeeding (≥5 months) in high-risk 
infants, increased the risk of sensitization to egg white and the children were more 
commonly diagnosed with eczema at 1 year of age (but not at 2 years) 245. Lastly, a 
New Zealand birth cohort following children from age 3 and assessed every 2-5 years 
from age 9 to 26 years showed that breast-fed children were more commonly 
sensitized to common allergens compared to non-breastfed children at all ages 
analyzed 246. Of note, the study assessed breastfeeding habits retrospectively at age 3 
years, with a potential increase in errors due to confounding factors. 
 
A major reason to the controversy in the literature is attributed to flaws and 
differences in experimental layout. This was illustrated in a multidisciplinary review 
revising the literature regarding breastfeeding and allergies between 1966 and 2001, 
where only 56 out of 4323 studies were considered conclusive 247. One major limitation 
in the methodology of these studies is the inevitable natural bias due to the incapacity 
 
 
 30
to randomize infants to a non-breastfeeding control group and the inability to perform 
blinded breastfeeding. Another important bias is the inclination of mothers with 
allergic disease to breastfeed longer due to the known health benefits of breast milk. 
However, other important factors, such as family history of allergies, duration and 
exclusiveness of breast-feeding, socio-economic status, lifestyle 248, smoking, country 
of origin etc., are likely to play a role as well 249 and should be controlled for when 
possible. 
 
1.4.2.4 Breast milk-derived exosomes 
 
Our current knowledge on the function of breast milk exosomes is scarce. In 2007, 
Admyre et al in our group reported the presence of exosomes in human breast milk 
and showed their ability to induce regulatory Foxp3+CD4+ T cells in PBMCs 145. A 
following study by us further reported the presence of RNA in human milk exosomes 
that could be transferred to macrophages, supporting the notion that milk-derived 
exosomal RNA can be shuttled between cells 109. 
 
Additional studies have mainly focused on analyzing RNA content in milk exosomes. 
Data by Zhou et al show that exosomes in human milk are enriched in immune-
relevant miRNAs (30b, 182, 200a and 148a) 250 with the most abundant being miRNA 
148a, also highly enriched in bovine milk 251. These miRNA are resistant to degradation 
when subjected to multiple freeze and thaw cycles, prolonged incubation in room 
temperature 251, to RNAse and acidic conditions 252, which can be explained by the 
encapsulation of miRNA within vesicles. Recently, an interesting study was able to 
detect exogenous plant miRNA from food in the sera and tissue of several animals, 
suggesting their durability in the stomach and ability to reach systemic circulation 253. 
Thus, it is tempting to speculate that breast milk-derived exosomes carrying proteins 
and genetic material could be transferred to the child and affect the newborn’s 
immune system. 
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2 AIMS 
Exosomes are nano-sized vesicles capable of modulating immune responses by 
orchestrating communication between cells. Exosomes isolated from body fluids are 
by far the most physiological population of exosomes to study. Therefore, research on 
these exosomes is more likely to yield in vivo relevant results, as opposed to studying 
exosomes isolated from in vitro cell cultures. Yet, few studies so far have focused on 
body-fluid exosomes, and less so from those of human samples. Therefore, in this 
thesis I wanted to explore the immunological role of exosomes extracted from two 
immunologically active mucosal sites – the healthy and diseased lung and the 
mammary gland during lactation.  
 
The presence of BALF-exosomes exhibiting a DC-exosome-like phenotype in lung of 
healthy individuals 226, suggests that they might have a role in local immune responses. 
Therefore, study I and II were conducted to explore this possibility by analyzing BALF-
derived exosomes during health and during two separate inflammatory conditions, 
sarcoidosis (study I) and allergic asthma (study II).  
 
The specific aims were to: 
 
Study I: Characterize and functionally compare BALF isolated exosomes from patients 
with pulmonary sarcoidosis and healthy individuals. 
 
Study II: Characterize and functionally compare BALF exosomes from birch sensitized 
asthmatic patients and healthy individuals.  
 
Breastfeeding is known to protect against infections and might influence allergy 
development in the child. Differences in immune components in breast milk between 
mothers might lead to differences in immune modulation and allergic outcome of the 
child. Therefore, in study III we aimed to explore potential differences that might exist 
in the composition of breast milk-exosomes between mothers with regard to 
sensitization and lifestyle.  Finally, due to the known protective role of breastfeeding 
against infections, in study IV we wanted to investigate the possibility of breast milk-
exosomes being one protective factor against HIV-infection. 
 
The specific aims were to: 
 
Study III: Compare the composition of breast milk exosomes with regard to allergic 
status (IgE-sensitized or non-sensitized) or lifestyle (anthroposophic/non-
anthroposophic) of the mother. 
 
Study IV: Address whether human milk exosomes could prevent against HIV infection 
in DCs and subsequent trans-infection of T cells.  
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3 MATERIALS & METHODS 
3.1 STUDY POPULATIONS 
3.1.1 SARCOIDOSIS PATIENTS – STUDY I 
All individuals included in this study were recruited from the Karolinska University 
Hospital, Stockholm, Sweden. Sarcoidosis patients were subjected to bronchoscopy 
and bronchoalveolar lavage (BAL) as part of a routine investigation for sarcoidosis. 
Diagnosis of the disease was established by clinical manifestations, radiological 
findings, analysis of BAL cells with elevated levels of CD4+/CD8+ T cell ratio and 
presence of granulomas by histology of bronchoscopic biopsy specimen. All healthy 
individuals were non-smokers, had normal chest X-rays and no previous respiratory 
infections for at least one month prior to BAL. 
 
3.1.2 BIRCH ASTHMATICS – STUDY II 
This work included mild birch asthmatics and healthy individuals all recruited from the 
Karolinska University Hospital. All patients had birch pollen-specific IgE in serum (≥2.0 
kU/L) whereas controls were negative (≤0.35 kU/L). Patients were free of asthma 
exacerbations and lung infections at least 4 weeks prior to BAL with occasional 
medication with β2-agonist. BAL was performed according to established protocols 
254 and was collected once from healthy controls and twice from asthmatics (before 
and after allergen challenge) with a minimum of 3 weeks between first- and second 
BAL. 
 
3.1.3 ANTHROPOSOPHIC AND ALLERGEN SENSITIZED MOTHERS – STUDY III 
This study was based on the prospective birth cohort study ALADDIN (Assessment of 
Lifestyle and Allergic Disease During INfancy) 255. Breast milk was collected at 3-8 
days and at 2 months after delivery. Mothers were characterized as anthroposophic or 
non-anthroposophic according to answers to a questionnaire. IgE-sensitization was 
determined if IgE-levels were ≥0.35 kU/l for the parents measured by Phadiatop® 
(kindly sponsored by Phadia AB) and for the children at 2 years of age by 
ImmunoCAP® in at least one of the seven allergens. 
 
3.1.4 BREAST MILK AND BLOOD FROM HEALTHY INDIVIDUALS – STUDY IV 
This study included human samples (breast milk, plasma and PBMCs) from healthy 
individuals. Human breast milk was collected at home from healthy volunteers that 
were non-smokers, had vaginal deliveries at full-term and had normal birth weight 
infants. Plasma and buffy coats for PBMC isolation were collected from healthy blood 
donors and were recruited from the Karolinska University Hospital.  
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3.1.5 ETHICAL PERMISSION 
The local ethics committee approved all studies included in this thesis and all subjects 
participated voluntarily and provided written informed consent.   
 
3.2 METHODS 
The listed methods below were used in study I-IV of this thesis. A description of the 
following methods can be found in the respective publications. 
 
 Bronchial epithelial cell culture (study I & II) 
 
 Bronchoalveolar lavage (BAL) (study I & II) 
 
 Confocal microscopy (study IV) 
 
 Cytospin and May-Grünwald-Giemsa (study II)  
 
 Electron microscopy (study I) 
 
 Enzyme-linked immunosorbent spot (ELISPOT) (study I) 
 
 Endotoxin test (study I) 
 
 Enzyme-linked immunosorbent assay (ELISA) (study I & II) 
 
 Exosome isolation with ultracentrifugation and immunoadsorption (study I-IV) 
 
 Flow cytometry analysis (study I-IV) 
 
 Generation of monocyte-derived dendritic cells (MDDCs) (study IV) 
 
 High performance liquid chromatography (HPLC) (study II) 
 
 Mass spectrometry analysis (study I) 
 
 Silver staining of gel  (study I) 
 
 Statistical analysis (study I-IV) 
 
 Sucrose gradient fractionation (study I & IV) 
 
 Western blot analysis (study I & II) 
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4 RESULTS AND DISCUSSION 
4.1 PRO-INFLAMMATORY EXOSOMES IN SARCOIDOSIS (STUDY I) 
Various studies of sarcoidosis, including genetic studies and cell and cytokine analysis 
in BALF, have provided important insights into the mechanisms involved in the 
disease 201, 256. However, we still do not fully understand the immunological events 
involved in the pathogenesis of sarcoidosis, partly due to the lack of a relevant animal 
model.  
 
In 2003, Admyre et al reported the presence of exosomes carrying immune-relevant 
molecules in BALF from healthy individuals 226, suggesting a role of exosomes in local 
immune defenses. Consecutive studies in mice have reported diverse functions of 
BALF exosomes, with studies showing a pro-inflammatory 226 or tolerogenic effect 224 . 
These studies imply that exosomal function varies with regard to the biological 
context of the lung. At the time that our study was initiated, there were no available 
data on the function of BALF exosomes in humans. Yet, based on data from the 
murine system, we hypothesized that human BALF exosomes from healthy individuals 
might be functionally different compared to exosomes from BALF of patients 
suffering from lung inflammation. Thus, we sought to determine the function of BALF 
exosomes from healthy individuals and sarcoidosis patients in the context of 
inflammation. 
 
Patients with pulmonary sarcoidosis exhibit an enhanced cellular infiltration and cell 
activation in BALF 257, 258, with potential effects on exosomal release as a consequence. 
Therefore, we hypothesized that levels of exosomes might differ in BALF from 
sarcoidosis patients compared to healthy controls. Accordingly, we found a significant 
increase in BALF exosomes in patients compared with healthy individuals (study I, 
figure 1A). In addition, we found an aberrant increase in several proteins on exosomes 
from patients compared to healthy controls, such as HLA-DR (study I, fig 2B and 4C), 
CD9, CD54 (study I, fig 2D and E) and HSP70 (study I, fig 4C). Taken together, we 
show that BALF exosomes from sarcoidosis patients are altered with regard to 
quantity as well as protein composition compared to those from healthy subjects. 
 
By mass spectrometry analysis we identified the presence of neuregulin-1 (NRG1) on 
BALF exosomes (study I, Table 2) and by Western blot we confirmed an enrichment 
of this molecule in BALF exosomes from patients compared to exosomes from healthy 
controls (study I, fig 4C-D). In the human lung, NRG1 has been reported to function as 
a growth factor for pulmonary epithelial cells 259. In addition, patients with acute lung 
injury display elevated levels of NRG1 in BALF and levels correlated with markers of 
inflammation 260. Whether these results can be extrapolated to patients with other 
inflammatory diseases is not known. However, it is tempting to speculate that NRG1-
expressing BALF exosomes could function as a new marker of inflammation and 
disease severity in sarcoidosis. 
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To study a potential immune function of BALF exosomes we exposed PBMCs from 
patients and healthy controls to BALF exosomes in an autologous setting, and 
measured the production of IL-13 and IFNγ as a readout of inflammation (study I, fig 
5A-B). We found that PBMCs from patients produced significantly higher levels of IL-
13 and IFNγ in response to BALF exosomes compared to those from healthy 
individuals, suggesting a pro-inflammatory function of exosomes from patients. 
Furthermore, due to the crucial involvement of airway epithelium in the initiation of 
immune responses in the lung 261, we next wanted to study the immune-modulatory 
effects of BALF exosomes on the bronchial epithelial cell line (BECs) 16HB14. We 
found that these cells released significantly higher levels of the pro-inflammatory 
cytokine IL-8 in response to exosomes from patients compared to those from healthy 
individuals (study I, fig 5C-D). Thus, our data suggests a pro-inflammatory function of 
BALF exosomes from patients with the ability to engage in both innate- and adaptive 
immune responses (see fig 4). 
 
Further studies could help elucidate the mechanism of exosome-mediated immune 
activation in PBMCs observed in this study. We speculate that BALF exosomes 
carrying MHC-peptides could present antigens to T cells and thereby evoke an 
inflammatory response. Alternatively, they could evoke antigen-specific responses by 
transferring antigens and/or peptide-MHC molecules to recipient APCs in order to 
amplify an immune response 114, 115. The mechanism by which BALF exosomes induce 
IL-8 in BECs is probably different from that in PBMCs. The striking similarities in clinical 
manifestations of tuberculosis and sarcoidosis, together with the finding of 
mycobacterial DNA in sarcoidosis samples 196, strongly suggest that MTB infection 
may function as an etiological agent of sarcoidosis (at least in a subgroup of patients). 
Previous studies have demonstrated the presence of mycobacterial components on 
BALF exosomes from M. bovis-infected mice with the ability to induce TNFα 
responses in naïve macrophages 229. Thus, we hypothesize that BALF exosomes from 
sarcoidosis patients might carry pathogen-derived molecules that could induce 
activation in BECs through PRRs.  
 
The up-regulation of HSP70 on BALF exosomes from patients compared to healthy 
controls is intriguing. Heat shock proteins are mainly located in the cytosol where they 
help maintain homeostasis by functioning as molecular chaperons. However, during 
abnormal conditions, such as during malignancies, HSP70 is upregulated and 
aberrantly located at the plasma membrane and can exert immunogenic functions 262. 
Mycobacteria-infected macrophages have been shown to release exosomes enriched 
in HSP70, particularly at the exosomal membrane compared to exosomes from non-
infected cells. Accordingly, exosomes enriched in HSP70 could trigger TNFα release at 
similar levels as those obtained by soluble HSP70, suggesting that HSP70 containing 
exosomes can function as potent inducers of inflammation 263. In our study, we did not 
determine whether HSP70 was present at the surface or within BALF exosomes. 
However, it appears plausible that the aberrant expression in HSP70 in exosomes from 
patients might contribute to their pro-inflammatory functions. 
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Taken together, this is the first study reporting a function of BALF exosomes from 
humans. Furthermore, we provide firm evidence of a pro-inflammatory function of 
BALF exosomes from sarcoidosis patients. These studies could help pave the way for 
future studies exploring the role of exosomes in sarcoidosis pathology and/or the 
involvement of lung exosomes in other pulmonary inflammatory diseases. 
 
Figure 4. Suggested role of BALF exosomes as promoters of lung inflammation in sarcoidosis.  
During sarcoidosis inflammation there is an increased release of pro-inflammatory exosomes that can stimulate 
IL-8 production in BECs, and IFNγ and IL-13 in T cells, which may contribute to granuloma formation. AM: alveolar 
macrophages, BECs: bronchial epithelial cells. 
 
 
4.2 EXOSOMES AS MEDIATORS OF LEUKOTRIENE-PRODUCTION IN ASTHMA 
(STUDY II) 
In study I, we found that exosomes in BALF from sarcoidosis patients exhibit pro-
inflammatory functions in vitro. Therefore, we wanted to study how these results 
could be compared to other inflammatory diseases in the lung.  We therefore aimed to 
study BALF exosomes in allergic asthma – a chronic inflammatory disease driven by a 
distinct set of inflammatory cells and cytokines compared to sarcoidosis inflammation.  
 
In contrast to our findings on BALF exosomes isolated from sarcoidosis patients, we 
found no difference in the levels of exosomal protein in BALF of healthy individuals 
compared to those with allergic asthma, neither before nor after allergen challenge 
(study II, fig 1E). This is in accordance with our results showing no difference in cell 
numbers in the BALF between healthy subjects and asthmatics (study II, figure 1D), 
suggesting a limited allergic reaction. Nevertheless, we found enrichment in several 
exosomal-proteins in BALF from patients compared to those from healthy individuals, 
both at steady state and after allergen challenge (study II, fig 2A-F). This suggests an 
intrinsic alteration in exosome composition in BALF of patients with allergic asthma. 
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Previous studies by Esser et al found functional leukotriene (LT)-producing enzymes 
in exosomes from human DCs and macrophages 264. LTs are key mediators of 
inflammation, and therefore, we wanted to investigate whether these enzymes were 
present in BALF exosomes. Accordingly, BALF exosomes from asthmatics and healthy 
subjects contained abundant levels of several LT-enzymes, including LTA4H and 
LTC4S (study II, Fig 4A). Most importantly, these enzymes were functional (study II, fig 
4B) and had similar capacities for conversion of LTA4 as APC-derived exosomes 
264. 
However, BALF exosomes had a higher LTA4H activity relative to LTC4S, while the 
opposite was found for APC-derived exosomes 264, suggesting that BALF exosomes 
might originate from other cell types than APCs. 
 
To gain insights into the function of BALF exosomes in asthma, we made use of the 
BEC line 16HB14, which we exposed to BALF exosomes from asthmatics or healthy 
controls and subsequently measured the release of LTs and IL-8. We discovered that 
BECs produced significantly greater levels of IL-8 and LTs (mainly LTC4) in response 
to BALF exosomes from asthmatics compared to controls, with no difference before 
and after allergen challenge (study II, fig 5A-B). This further reinforces an inherent or 
latent inflammatory activity of exosomes from patients. Furthermore, the induction of 
LTs in response to BALF exosomes from patients could be efficiently reduced upon 
treatment with the CysLT1 receptor antagonist montelukast (study II, fig 5C), which 
suggests that exosome-induced IL-8 production I BECs is at least partly mediated by 
CysLTs. Taken together, these results imply that exosomes in BALF might assist in the 
production of pro-inflammatory cytokines and LTs in airway epithelial cells and 
thereby promote lung inflammation (see fig 5). 
 
 
 
 
Figure 5. Suggested role of BALF exosomes in the pathogenesis of allergic asthma. During inflammation, 
exosomes are able to induce IL-8 and CysLT-production in BECs, which further helps in the recruitment of 
inflammatory cells to the lung. AM: alveolar macrophages, BECs: bronchial epithelial cells. Upper panel; 
inflammatory condition. Lower panel; healthy condition.  
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In contrast to our results, a recent study using a murine OVA-model of allergic airway 
inflammation found that exosome secretion, as well as total cell count was higher in 
BALF of asthmatic mice compared with controls 142. Since our study included patients 
with mild asthma, we speculate that more severe cases of allergic asthma could 
potentially yield an increase in exosome production relative to non-inflammatory 
conditions. Nevertheless, our results show detectable differences in exosomal protein 
composition between asthmatics and healthy individuals, even in the absence of 
clinical symptoms. Previous studies have confirmed that even asthmatics with a mild 
form of airway inflammation show features of lung inflammation at steady state, such 
as increased levels and activation state of airway eosinophils and T cells, increased 
epithelial shedding, increased frequencies of hypodense macrophages and enlarged 
thickness of the basal membrane 265-267. Thus, the altered exosome phenotype in 
patients during “steady state” could be due to an ongoing subclinical lung 
inflammation. 
 
The detection of functional LT-producing enzymes in BALF exosomes from healthy 
individuals supports a role for exosomes in lung immunity. In fact, previous studies on 
tracheobronchial epithelium-derived exosomes have shown their ability to neutralize 
influenza virus via sialic acid moieties 141, suggesting the involvement of exosomes in 
regulating host defense reactions in the lung. Our study implies that LT generation by 
BALF exosomes from healthy individuals might constitute an additional mechanism 
for efficient immune responses against infectious agents. In the context of host 
defense, large amounts of LTA4 produced by infiltrating neutrophils could potentially 
be metabolized into LTs by LT-producing enzymes present in BALF exosomes and 
thus facilitate pathogen clearance. Although human exosomes from plasma also carry 
functional LT-producing enzymes 264, we detected 50 times more LTs from LTA4 
generated by BALF exosomes compared to those isolated from plasma. This further 
emphasizes the relevance of BALF exosomes in lung immunity in healthy individuals.  
 
Not all cells are equipped with all the cascade enzymes necessary for LT production. 
Despite this, cells expressing either LTA4H or LTC4S have the potential capacity to 
produce LTs due to the intercellular transfer of LTA4. This phenomenon called 
“transcellular metabolism” has been reported for several cell types including human 
airway epithelial cells 268. In addition, further studies have shown that human BECs 
express an active- and inducible 5-LO pathway upon activation and can generate de 
novo LT-synthesis 269. This corroborates our findings on LT-production in BECs and we 
further show that BALF exosomes from asthmatics boosts LT production in these 
cells. How exosomes induce LT-synthesis in BECs is currently not known. However, we 
hypothesize that transfer of LT-enzymes to BECs via exosomes could potentiate their 
LT-synthesizing capacity. Alternatively, BALF exosomes could potentially induce the 
expression of LT enzymes in BECs by delivering pro-inflammatory stimuli to the cells.  
 
One of the caveats with this study is the limited number of patients and the fact that 
exosomes from BALF were isolated at one single time point after allergen challenge. 
Asthmatics were subjected to BAL 24 h after allergen provocation, which likely 
reflects a resolution phase of the inflammation 270. In fact, previous analysis of BALF 
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cells and cytokines from the same individuals exhibited an increase in CD4+Foxp3+ T 
cells and IL-10 at this particular time-point 271. This suggests that anti-inflammatory 
mechanism have already been initiated at 24 h in order to counteract inflammation. 
Therefore, the lack of phenotypic and functional differences seen between BALF 
exosomes from asthmatics before and after allergen challenge could be due to the 
late time-point of choice. Explorations of other time-points may therefore reveal novel 
functional differences between BALF exosomes from asthmatics before and after 
allergen challenge. Nonetheless, this is the first study characterizing BALF exosomes 
in allergic asthma and adds to our knowledge about the role of exosomes in the 
human lung.  
 
4.3 BREAST MILK EXOSOMES IN RELATION TO LIFESTYLE AND ALLERGIC 
SENSITIZATION (STUDY III) 
Both environmental and genetic factors are known to strongly influence allergy 
development 272, 273. Environmental exposures pre-natally and/or during early 
childhood, including diet, are thought to play a vital role on allergic outcome later in 
life 273. Breastfeeding has long been known to provide immune-related benefits to the 
child 242. As a result, extensive research has attempted to establish a relation between 
breastfeeding and allergy development in the child. However, the results obtained 
have been controversial, with studies reporting a protective effect of breast-feeding 
on allergic outcome, while others support a promoting, or a neutral effect 249.  Notably, 
differences in the immune profile of breast milk have been reported between mothers 
with regard to maternal allergies 274, 275 and environmental exposures 276. Therefore, it 
has been postulated that at least part of the discrepancies between the outcomes 
could be attributed to individual variations in immune content of breast milk. 
 
Previous studies have shown that exosomes isolated from human breast milk have the 
ability to modulate immune responses in vitro 145, suggesting a potential impact on the 
child’s immune system. Here we aimed to address potential phenotypic differences in 
exosome composition in breast milk from mothers with regard to allergic sensitization. 
In addition, we wanted to address whether differences in maternal lifestyle, which 
implies differences in environmental exposures, could also affect exosome 
composition. For this purpose we chose to study the anthroposophic lifestyle since 
this way of living has previously been associated with a reduced risk of developing 
allergies in children  248, 255, 277, 278. Ultimately, we sought to determine whether 
differences in exosomal phenotype in the mother’s breast milk associate with allergic 
sensitization of the child at 2 years of age.  
 
Breast milk comprises a mixture of different cell types 237. Accordingly, our data 
suggest that human breast milk also contains phenotypically different subpopulations 
of exosomes. We approached the analysis by immunoprecipitating exosomes using 
beads coated with anti-MHC class II or anti-CD63 antibodies. This isolation method 
allowed us to precipitate exosomes with different ratios of CD63/MHC class II 
expression as seen by flow cytometry, thus supporting the existence of phenotypically 
different exosomes in breast milk (study III, fig 2C) (see fig 6).  
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We then analyzed the expression of several surface proteins on subpopulations of 
exosomes from mothers with regard to sensitization and/or lifestyle (study III, fig 3). 
We found that allergen-sensitized mothers had a decrease in MUC1 expression on 
exosomes bound to anti-CD63-coated beads compared to those from non-sensitized 
mothers (study III, fig 3H). Strikingly, the same molecule was decreased on exosomes 
from anthroposophic versus non-anthroposophic mothers, but this was only apparent 
when analyzing exosomes selected on anti-MHC class II-coated beads (study III, fig 
3L). In addition, the tetraspanin CD63, which is highly enriched on breast milk-
exosomes, was found to be upregulated on CD63-selected exosomes from 
anthroposophic mothers compared to non-anthroposophic women (study III, fig 3M). 
Since flow cytometry analysis of exosome-coated beads does not allow for exosome 
quantification, differences in the expression of surface molecules on exosomes may 
reflect an increase/decrease in the numbers of exosomes expressing that particular 
molecule, or a selective enrichment/decrease of surface molecules on exosomes. 
Nonetheless, our data suggests that maternal sensitization and lifestyle influences the 
phenotype of different subpopulations of exosomes in human breast milk. 
   
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Isolation of exosomes on anti-CD63 latex beads or anti-MHC class II Dyna beads and detection by 
flow cytometry. 
 
 
Next we wanted to correlate our results with sensitization outcome of the breast-fed 
children. To our surprise, we found that children that developed allergic sensitization 
at age 2 had been breastfed by mothers that exhibited significantly higher levels of 
MHC class I on exosomes bound to anti-CD63-coated beads (study IV, fig 4C). While 
these observations are interesting, further studies are required to elucidate a potential 
effect of these phenotypic observations on allergic outcome. Furthermore, despite 
detected differences in MUC1 expression on milk-exosomes with regard to maternal 
sensitization and lifestyle, we were unable to detect an association between MUC1 
expression and allergic-sensitization in the child (study III, fig 4D). However, the low 
number of children who developed IgE-sensitization in our study could partly explain 
the lack of association. Thus, future studies including a bigger group of children could 
help address this. 
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The finding that MUC1 levels were altered on exosomes in mothers with respect to 
sensitization and lifestyle is intriguing. However, the potential immune-effects of these 
phenotypic alterations are currently elusive. Secreted MUC1 in human milk is known to 
be involved in pathogen binding, and thereby serving protective functions against 
infections 279, 280. Thus, we speculate that MUC1-bearing exosomes in breast milk could 
function as decoy receptors for pathogens and facilitate their clearance.  Accordingly, 
the lower expression of MUC1 on exosomes from anthroposophic mothers fits well 
with the hygiene hypothesis, which postulates that early exposure to infectious agents 
protects against allergy development later in life 281. Thus, if allowed to speculate, 
children breastfed by anthroposophic mothers would receive less MUC1 on exosomes 
through breast milk, which could render them more susceptible to infections and less 
likely to develop allergies as a consequence. In addition to the reported role of MUC1 
on pathogen binding, it has also been described as a ligand for the adhesion molecule 
CD54 282. Therefore, MUC1-expressing exosomes could potentially mediate cell 
interactions with CD54-expressing immune cells in the gut or endothelial cells, which 
could constitute a mechanism to enter systemic circulation.  
 
The finding that CD63 was significantly increased on exosomes from anthroposophic- 
compared to non-anthroposophic mothers is interesting due to the important roles of 
tetraspanins in the immune system 283.  For instance, tetraspanins provide organization 
of proteins and are thought to facilitate interactions with important immune-related 
molecules, such as MHC class II 284. However, little is known about the role of 
tetraspanins on exosomes but studies have suggested a function in antigen-
presentation, exosome production 284 and mediating cell-targeting 285. 
 
Taken together, our results provide valuable insights into how maternal sensitization 
and lifestyle might affect the exosome profile in human breast milk. Nevertheless, we 
are far from fully understanding how these results relate to outcome of allergic 
sensitization in the child. Hence, future studies exploring the biological function of 
MUC1-bearing exosomes and the function of phenotypically different subpopulatios of 
exosomes will be vital to reveal these complicated relations. 
 
4.4 HUMAN BREAST MILK EXOSOMES INHIBIT HIV INFECTION OF DCs (STUDY 
IV) 
Despite the health benefits associated with breastfeeding, breastfeeding by HIV-
positive mothers is highly controversial since HIV can be transmitted to the child 
through breast milk 286. Surprisingly, a number of studies have reported a significantly 
lower risk of HIV infection in exclusively breastfed- versus mixed- or formula-fed 
children 287, 288, pointing towards a protective effect of breast milk against HIV-
infection. In fact, several components in milk have been suggested to mediate 
protection against HIV. One example is MUC1, which has been shown to compete with 
HIV for binding to DC-SIGN on DCs, resulting in the inhibition of HIV transfer to T cells 
289. DCs can, however, also be productively infected by HIV by exploiting innate 
signaling through DC-SIGN 27, among other mechanisms  290. 
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The presence of MUC1 on exosomes from human breast milk (study III) led us to 
speculate that milk-exosomes could have an effect on HIV infection in DCs and or 
trans-infection of T cells. As a comparison we used exosomes from another body fluid, 
namely plasma-derived exosomes. We conditioned MDDCs with milk-exosomes or 
plasma-exosomes for 1 h prior to infection with HIV-1BaL for 4 h followed by extensive 
wash and incubation at 37oC. For viral transfer experiments, MDDCs pre-exposed to 
exosomes and HIV-1BaL were thereafter co-incubated with allogeneic CD4
+ T cells. 
Subsequently, MDDCs or T cells were analyzed for productive infection (p24+) by flow 
cytometry after 5 days in culture.  
 
We found that breast milk exosomes, but not plasma exosomes, significantly reduced 
productive infection of MDDCs (study IV, fig 1B-D). Moreover, MDDCs that were pre-
conditioned with milk-exosomes, but not with plasma-exosomes, were significantly 
less efficient in trans-infecting T cells (study IV, fig 2). Therefore, these results suggest 
that milk-exosomes act on DCs, thereby suppressing DC infection and subsequent 
infectivity of T cells. 
 
To gain insights into exosome-DC interaction, we labeled exosomes with a lipid dye 
and measured uptake by MDDCs by flow cytometry and confocal microscopy at 
different time points (30 min, 1 h, 2 h and 4 h). By confocal microscope analysis, we 
could determine that exosomes accumulated readily and most prominently inside the 
cell already after 2 hours (study IV, fig 3A). However, by flow cytometry analysis (a 
quantitative and more sensitive detection method), we found detectable levels of 
exosome-uptake/binding already after 30 min, with the most notable interaction 
occurring at 1 h (study IV, fig 3B). In contrast, no uptake of plasma-exosomes could be 
detected up to 4 h (study IV, data not shown). In conclusion, these results show that 
milk-exosomes are efficiently taken up by MDDCs and suggests a selective uptake of 
milk-exosomes, since no uptake was observed with plasma-exosomes within this time 
frame. 
 
DC-SIGN and adhesion molecules, such as CD54, have previously been shown to 
mediate interactions with HIV 291, 292. Based on this, we reasoned that both DC-SIGN 
and CD54 might constitute potential binding and entry-points for exosomes to cells, 
and could provide an explanation to the blocking effect of milk-exosomes on HIV 
infection. Therefore, to study the contribution of these receptors in exosome-uptake, 
we blocked DC-SIGN and/or CD54 on DCs and subsequently measured exosome-
uptake by confocal microscopy and flow cytometry analysis. We found that cells 
treated with isotype control or CD54 antibodies efficiently took up exosomes, 
whereas blocking DC-SIGN on DCs completely abolished exosome-uptake, seen by 
confocal microscopy analysis (study IV, fig 4A). Nevertheless, by flow cytometry, we 
detected a certain degree of exosome uptake in DCs blocked with DC-SIGN at 30 min 
post incubation, albeit at lower levels compared to isotype- and CD54 treated cells 
(study IV, fig 4B). Of note, the difference between anti-DC-SIGN and anti-CD54-
treated cells was reduced over time, possibly due to uptake via alternative routes 
and/or internalization and recycling of DC-SIGN to the cell-surface 293.   
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The notion that exosomes can interact with cells has been well documented. However, 
the mode of interaction still remains unclear. Studies suggest that phagocytic cells 
mainly take up exosomes through phagocytosis, whereas non-phagocytic cells 
interact with exosomes at the cell-surface 294. Additional studies by Morelli et al further 
reinforce the notion that exosomes are internalized efficiently by phagocytic cells, 
including DCs 111. In line with these observations, we found that MDDCs were capable of 
internalizing milk-exosomes, while incapable of internalizing plasma-exosomes within 
the time-span of 4 h. Therefore, our data suggest that the mode of interaction 
between phagocytic cells and exosomes might depend on the type of exosomes, and 
could potentially involve surface binding 124, direct fusion 295, 296, and/or internalization. 
We report a previously unknown mode of interaction between exosomes and DCs 
involving the binding of DC-SIGN. However, whether this particular interaction 
mediates the internalization of milk-exosomes is not clear. Nevertheless, as seen by 
confocal microscopy analysis, blocking of DC-SIGN led to reduced exosome 
internalization in MDDCs (study IV, fig 4A), suggesting a role of DC-SIGN in exosome-
uptake. However, other routs of entry are likely also involved since blocking of DC-
SIGN resulted in partial inhibition in exosome-binding/uptake.  
 
We speculate that MUC1 on exosomes might be mediating interactions with DC-SIGN. 
In fact, DC-SIGN has previously been reported to recognize and bind Lewis X 
structures present on MUC1 289. However, we cannot exclude the contribution of other 
DC-SIGN ligands that might be present on exosomes, such as other glycans containing 
similar binding motifs. We further postulate that the protective effect of milk-
exosomes on HIV-infection is, at least partly, DC-SIGN mediated. We speculate that 
this could occur by the ability of milk-exosomes to: 1) outcompete HIV for the binding 
of DC-SIGN, 2) target DC-SIGN for lysosomal degradation, and/or 3) induce DC-SIGN 
signaling with potential effects on DC-function. However, it is possible that additional 
mechanisms, such as the binding of exosomes to other co-receptors for HIV entry, 
such as CCR5, could account for the protective effect. Also, other non-specific 
mechanisms, such as induced maturation of DCs by milk-exosomes, could potentially 
account for a lower infectivity rate. In fact, previous studies suggest that mature DCs 
are less vulnerable to HIV infection 297. Yet, we found that DCs expressed similar levels 
of the maturation marker CD86 before- and after exosome-exposure, which would 
argue against such a mechanism. In contrast, T cell activation seems to be a major 
factor facilitating HIV-infection in these cells 298. Thus, we cannot exclude an indirect 
effect of exosomes by affecting T cell activation. However, since we washed DCs prior 
to co-culture with T cells, this explanation appears unlikely since the washing step 
likely removes any unbound exosomes. However, future studies are required to 
address the underlying mechanisms. 
 
Studies have shown that HIV infected cells can secrete exosomes that carry viral 
proteins and viral-derived small RNAs 299, which might be important for mediating 
viral spread. Therefore future studies will have to address whether HIV-positive 
mothers carry viral-containing exosomes in their breast milk. Furthermore, revealing 
the ratio of HIV-containing exosomes versus HIV-negative exosomes in breast milk of 
 
 
 44
HIV positive mothers will be helpful in trying to decipher the overall effect of milk-
exosomes on HIV transmission from mother-to-child. 
 
In summary, our data show that breast milk-exosomes inhibit productive HIV infection 
of MDDCs and subsequent trans-infection of CD4+ T cells. Furthermore, we show that 
exosomes bind to DCs through a mechanism that is partly dependent on exosome-
DC-SIGN interactions. Therefore, we suggest that milk-derived exosomes may play a 
role in lowering the risk of HIV-1 transmission by breastfeeding. We propose a 
mechanistic model in which exosomes compete with HIV for the binding to DC-SIGN 
and thereby provide protection against HIV infection in DCs and trans-infection to T 
cells (see fig 7).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. Proposed mechanism for breast milk exosome-mediated protection against HIV-infection. Exosomes 
with MUC1 on the surface bind to DC-SIGN on DCs and thereby block entry of HIV and subsequent viral transfer to 
T cells. 
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5 CONCLUSIONS 
Study I: This study shows that patients with sarcoidosis have increased production of 
exosomes in their lungs compared to healthy individuals. These exosomes have the 
ability to stimulate cytokine production from autologous PBMCs and epithelial cells, 
suggesting both an adaptive and an innate mode of activation. These results suggest 
that exosomes from the BALF of patients with sarcoidosis might have a role in the 
pathogenesis of the disease and could be of relevance for the development of novel 
treatment strategies for sarcoidosis, but also for the development of new disease and 
prognostic markers for sarcoidosis. 
 
Study II: We show that BALF-derived exosomes from patients with allergic asthma 
have an altered exosome profile compared to healthy individuals, and that they exert 
pro-inflammatory functions by inducing the release of IL-8 and CysLTs in bronchial 
epithelial cells. Thus, our data suggest that BALF exosomes might contribute to 
asthma pathogenesis by promoting pro-inflammatory cytokines and LT generation in 
the lung. This could have implications in the development of future therapies targeting 
exosome production. 
 
Study III: In this study we found that human breast milk exosomes differ 
phenotypically between mothers with respect to their allergic sensitization and 
lifestyle. Therefore we suggest that changes in exosome-composition might 
differentially influence the immune system of the newborn with possible effects on 
allergy development as a consequence. 
 
Study IV: We show that pre-exposure to human breast milk derived exosomes 
reduces productive HIV-1 infection of monocyte-derived DCs and subsequent viral 
transfer to CD4+ T cells. This suggests that milk-exosomes might be one of the 
components that confer protection from HIV-1 transmission from mother to child 
through breastfeeding. 
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6 POPULÄRVETENSKAPLIG SAMMANFATTNING 
Kroppen består av olika celler som i ett strukturerat nätverk utgör skilda organen i 
kroppen, såsom lungor och tarm. För att organen ska kunna fungera normalt, så är det 
ytterst viktigt att cellerna kommunicerar med varandra. Denna kommunikation kan ske 
via beröring mellan celler som kräver direktkontakt. Det kan dock finnas situationer då 
det är omöjligt, eller rent av opraktiskt att behöva befinna sig på samma plats för att 
utbyta information. Ett utmärkt exempel på detta är kommunikationen mellan oss 
människor. Att kunna ses och skaka hand kan vara ett effektivt sätt att kommunicera, 
men omöjligt att utföra mellan två personer belägna på olika platser i världen. 
Däremot har vi möjligheten att kunna kommunicera via telefon, email, brev, Skype etc. 
Även vissa celler har utvecklat en rad mekanismer för att kunna kommunicera 
sinsemellan, trots att de är belägna vid olika platser i kroppen. Ett exempel på detta är 
exosomer. Alla celler i kroppen kan frisätta exosomer, mycket små sfäriska budbärare 
med förmågan att transportera information från en cell till en annan. Fördelen med 
exosomer gentemot att frisätta enstaka proteiner, såsom hormoner, är att exosomer 
kan bära på 100-tals molekyler som tillsammans kan leverera ett mer sofistikerat 
kommunikationsutbyte. Jag föreställer mig hormoner som ord ur en konversation, 
medan exosomer utgör hela meningar. 
 
Betydelsen av exosomer vid sjukdom och hälsa har gradvis börjat belysas. Man har 
hittills påvisat allt från sjukdomsalstrande till tolerans-inducerande funktioner, vilket 
tyder på en relativt komplex kommunikationsdynamik. Forskare har upptäckt att 
exosomer från olika celler kan innehålla olika typer av information, vilket delvis 
förklarar exosomernas skilda effekter. Exosomer har kunnat isoleras från alla mänskliga 
kroppsvätskor man analyserat hittills, som t ex. saliv, bröstmjölk, blod och urin, vilket 
tyder på en viktig funktion i kroppen. Genom att studera exosomer från kroppsvätskor 
hoppas vi kunna få en ökad förståelse för exosomers fysiologiska funktion. 
 
Vid varje andetag så exponeras lungorna för en mängd både ofarliga- och potentiellt 
skadliga faktorer. Av den anledningen är lungan utrustad med ett kraftfullt 
immunförsvar som kan skydda kroppen mot infektioner, men som även kan urskilja 
farligt från ofarligt. Trots detta händer det att immunsystemet attackerar harmlösa 
ämnen, eller förlorar striden mot sjukdomsalstrande virus eller bakterier, vilket leder till 
kronisk inflammation. En hypotes är att exosomer utgör små budbärare i lungan som 
kan leverera ”goda” nyheter under normala situationer, eller ”dåliga” nyheter under en 
inflammation. I arbete I och II studerade vi exosomer isolerade från lungvätska från 
patienter med sarkoidos och astma, två inflammationssjukdomar i lungan. Vi fann att 
exosomerna hade sjukdomsalstrande egenskaper och kunde jämfört med exosomer 
från friska individer bl.a. inducera en ökad grad av inflammatoriska substanser hos 
lungceller.  
 
Studier har tidigare klarlagt att amning kan skydda spädbarnet mot infektioner, och ha 
en eventuell skyddseffekt mot allergier. Resultaten angående allergiutveckling har 
däremot varit tvetydiga. En tidigare studie har visat att mammans bröstmjölk kan 
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variera i immunologiskt innehåll, vilket delvis kan förklara de motstridiga resultaten 
mellan olika studier. Vi har tidigare visat att exosomer i bröstmjölk har förmågan att 
inducera så kallade T celler med regulatoriska funktioner vilket kan ha betydelse för 
induktion av tolerans hos det ammade barnet. I studie III påvisade vi skillnader i 
sammansättningen av exosomer i mjölk mellan kvinnor med hänsyn till moderns 
allergiska status och livsstil vilket vi tror kan ha effekter på allergiutveckling hos det 
ammade barnet. 
I studie IV presenterar vi en ny kommunikationsmekanism mellan bröstmjölks-
exosomer och dendritiska celler, vilket är en typ av cell som spelar en ytterst viktig roll 
i immunförsvaret. Vi fann att mjölk-exosomer bär på signaler som cellerna specifikt 
känner igen. Förvånande nog så överförde exosomerna ett ökat skydd hos cellerna 
mot HIV infektion jämfört med celler som inte hade varit i kontakt med mjölk-
exosomer. Eftersom HIV-positiva mammor som ammar kan överföra HIV via mjölken, 
så skulle exosomer i bröstmjölk kunna utgöra en skyddande faktor mot HIV-infektion 
via amning genom att konkurrera med HIV för inbindning till immunceller.  
 
Sammanfattningsvis så har studierna inkluderade i den här avhandlingen gett en ökad 
förståelse för hur exosomer isolerade från bröstmjölk och lungor kan medverka i 
immunologiska processer. Vi är dock fortfarande i ett tidigt stadium och fler studier 
behövs för att få full förståelse för hur exosomer fungerar och interagerar med celler i 
kroppen. Men framtiden ser ljus ut och exosomer skulle kunna erbjuda en ny sorts 
terapi mot olika typer av sjukdomar. Man skulle t.ex. kunna slå ut sjukdomsalstrande 
exosomer i lungan under en inflammation, eller främja produktionen av tolerans-
inducerande exosomer i syfte att motverka sjukdomar, såsom allergier. 
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7 REFLECTIONS & FUTURE PERSPECTIVES 
Our work has shown that the amount of BALF exosomes- their protein and function 
differ between patients with sarcoidosis and healthy controls (study I). In addition, our 
findings that BALF exosomes from sarcoidosis patients and individuals with allergic 
asthma (study II) are able to promote pro-inflammatory cytokine release in vitro in 
BECs, suggest a contribution of these vesicles in driving inflammation in vivo. 
However, the mechanism of action by BALF exosomes might be disease-context 
dependent due to differences in the cellular make-up of the lung in patients with 
different pulmonary inflammatory diseases. Hence, further studies are required to 
characterize functional similarities and disparities of BALF exosomes between 
different lung inflammatory diseases. In the future, pro-inflammatory exosomes could 
potentially be targeted for therapeutic purposes and further insights on BALF 
exosome function in the context of a given disease could help develop tailor-made 
treatments. However, BALF exosomes, likely contain a heterogeneous population of 
exosomes as seen for exosomes in breast milk (study III). These different exosomes 
might carry out different functions depending on their cellular origin, and could 
include exosomes with tolerogenic functions that help counteract disease. Therefore, 
further studies need to focus on characterizing subpopulations of exosomes and other 
extracellular vesicles in BALF in order to understand their overall contribution in 
inflammation. In addition, detailed characterization of BALF exosomes from 
sarcoidosis patients by proteomics or microarray analysis could provide new insights 
on the composition of exosomes and reveal new biomarkers of sarcoidosis.  
 
It is well established that breast-feeding protects against enteropathic infections in the 
child 300 and has further been suggested to protect against other immune-related 
diseases, such as asthma, inflammatory bowel disease and multiple sclerosis 301-304. 
Hence, it has been hypothesized that breast milk might confer protection against 
diseases by promoting antigen-specific tolerance in the breastfed child 305. I therefore 
would like to explore a potential contribution of milk-exosomes in tolerance induction, 
both in vitro and in vivo. Furthermore, since breast milk likely contains different types 
of vesicles with potentially distinct or overlapping functions, I would like to investigate 
the immune-regulatory functions of two different vesicle-types in milk, exosomes and 
MVs.  
 
7.1 PRELIMINARY RESULTS 
Antigen-specific immune tolerance in vivo is thought to require antigen-presentation 
by “tolerogenic” DC in the mesenteric lymph nodes and following induction of 
antigen-specific Tregs 306. I therefore would like to address whether exosomes and/or 
MV can influence DC-biology towards a tolerogenic function by monitoring their 
capacity to induce Tregs. In order to test the role of breast milk exosomes and MVs in 
a mouse in vivo model, we first had to isolate and characterize murine milk vesicles 
since it has not previously been done. Exosomes and MVs were isolated from milk 
collected from pup stomachs 12 days postpartum by differential ultracentrifugation 
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research focusing on the differential “tolerogenic” function of milk-exosomes and MVs 
from mothers with regard to allergies or other immune-related diseases. Furthermore, 
the presence of phenotypically different sub-populations of exosomes in milk found in 
our study (study III) could be reflecting the existence of functionally different vesicles 
in breast milk, a research venue worth pursuing. 
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